WO2008134047A1 - Procédés de traitement de l'hypertension - Google Patents

Procédés de traitement de l'hypertension Download PDF

Info

Publication number
WO2008134047A1
WO2008134047A1 PCT/US2008/005451 US2008005451W WO2008134047A1 WO 2008134047 A1 WO2008134047 A1 WO 2008134047A1 US 2008005451 W US2008005451 W US 2008005451W WO 2008134047 A1 WO2008134047 A1 WO 2008134047A1
Authority
WO
WIPO (PCT)
Prior art keywords
ramipril
diketopiperazine
decomposition
blood pressure
hctz
Prior art date
Application number
PCT/US2008/005451
Other languages
English (en)
Inventor
Robert L. Rolleri
Charles L. Pamplin Iii
Original Assignee
King Pharmaceuticals Research And Development, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by King Pharmaceuticals Research And Development, Inc. filed Critical King Pharmaceuticals Research And Development, Inc.
Publication of WO2008134047A1 publication Critical patent/WO2008134047A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Definitions

  • the present invention relates to novel pharmaceutical compositions comprising ramipril in combination with other active agents. More particularly, the present invention is directed to a tablet comprising ramipril and hydrochlorothiazide.
  • the compositions of the present invention have improved stability of ramipril which is less susceptible to degradation relative to other compositions comprising ramipril alone or in combination with another active agent.
  • the present invention also relates to methods of making and methods of manufacturing such compositions.
  • the present invention also relates to methods of treating cardiovascular disorders such as hypertension by administering to a patient in need thereof a tablet formulation comprising a therapeutically effective amount of ramipril and hydrochlorothiazide, or administering to a patient a multi daily dose of ramipril that is more effective in treating hypertension than the equivalent amount of ramipril administered in a single daily dose.
  • Cardiovascular disease treatment has evolved rapidly over the last few decades to include agents that range in diversity from diuretics and natural products such as rauwolfia serpentina to agents such as angiotensin converting enzyme (ACE) inhibitors and calcium channel blockers (CCB).
  • ACE angiotensin converting enzyme
  • CB calcium channel blockers
  • Some of the conditions for which at least one of these agents has been used or is believed useful include, without limitation, hypertension, angina, myocardial infarction, atherosclerosis, diabetic nephropathy, diabetic cardiac myopathy, renal insufficiency, peripheral vascular disease, left ventricular hypertrophy, cognitive dysfunction, stroke, and headache.
  • agents useful for the treatment of cardiovascular disease and related conditions are apparent to those of ordinary skill in the art based on knowledge of the underlying mechanisms involved in certain conditions as well as on general clinical and pre-clinical experience (U.S. Patent No. 6,162,802, issued December 19, 2000 to Papa, et al.).
  • drug stability is an important consideration during the design, manufacture and storage of pharmaceutical compositions. Drugs that lack stability can degrade into degradant products which can cause side effects or, in some instances, can cause a decrease in the efficacy and bioavailability of the drug itself, making it difficult for doctors to prescribe consistent and effective treatments. This is applicable to the formulation of combination products and can be even more complex because of the inherent difficulties that accompany formulating combination products.
  • ACE inhibitors a class of drugs that is extremely useful in the treatment of cardiovascular disease, are susceptible to degradation, particularly when subjected to the stresses inherent to formulation processes.
  • Ramipril is an ACE inhibitor used in the treatment of cardiovascular disease, especially hypertension, and it is one of the most frequently prescribed drugs for congestive heart failure.
  • ramipril In hypertensive patients, ramipril is known to reduce peripheral arterial resistance causing a reduction in blood pressure without a compensatory rise in heart rate. Ramipril has also been shown to reduce mortality in patients with clinical signs of congestive heart failure after surviving an acute myocardial infarction. Ramipril may have an added advantage over many other ACE inhibitors due to its pronounced inhibition of the ACE enzymes in tissues resulting in organ protective effects in such organs as the heart, kidney, and blood vessels.
  • ramipril is without question one of the most important ACE inhibitors available today, like other ACE inhibitors, ramipril is susceptible to degradation. Indeed, current ramipril formulations show a considerable degree of instability. To date, the leading formulation of ramipril is a capsule. The degradation of ramipril is believed to occur mainly via two pathways: (a) hydrolysis to ramipril-diacid; and (b) cyclization or condensation to ramipril-diketopiperazine, also referred herein as ramipril-DKP. These ramipril-diacid and ramipril-DKP compounds form, as indicated above, as a result of cyclization, condensation and/or breakdown arising from exposure to heat, air, moisture, stress, compaction or other interactions or events.
  • ramipril needs special care when formulating into pharmaceutical preparations due the physical stress associated with the formulation process.
  • Factors that influence the stability of ramipril formulations are mechanical stress, compression, manufacturing processes, excipients, storage conditions, heat and moisture.
  • the physical stress associated with formulating tablets can increase the decomposition of ramipril into degradant products.
  • addition of other active agents to a ramipril tablet formulation could further increase the rate of ramipril decomposition and affect the potency or bioavailability of ramipril.
  • the potency or bioavailability of the other active agent can be adversely affected by the presence of ramipril in the formulation or during the formulation process.
  • PCT/EP2004/00456 describes solid ramipril compositions having suitably low water content and a process that utilizes excipients with low water content, in combination with processing parameters and packaging material that prohibit water or moisture uptake to formulate ramipril compositions and even though some formulations use glyceryl dibehenate, the rate of ramipril-DKP formulation is much higher than that in present invention. After one month the percent weight of ramipril-DKP is 2.14% at 40° C and at 75% humidity.
  • PCT/CA2002/01379 describes solid ramipril compositions that comprise a mixture of ramipril and lactose monohydrate as the diluent.
  • the process includes lactose monohydrate as the major excipient to formulate ramipril compositions in its attempt to improve ramipril stability.
  • lactose monohydrate the lowest rate of ramipril-DKP formation shows the presence of ramipril-DKP at 1.10%, immediately after formation of the capsule.
  • the present invention is directed to a tablet formulation comprising a therapeutically effective amount of ramipril and another active agent, such as a diuretic.
  • the present invention is directed to a tablet comprising a therapeutically effective amount of ramipril and hydrochlorothiazide.
  • the combination tablet comprising ramipril and hydrochlorothiazide can be formulated for once-a-day dosing. Once-a-day dosing allows for greater patient compliance since a patient would only have to take a tablet once daily instead of multiple times throughout the day.
  • the combination tablet comprising ramipril and hydrochlorothiazide is formulated for twice-a- day dosing.
  • the ramipril contained in the tablets of the present invention is stable against decomposition into such degradation products as ramipril-diacid or ramipril-diketopiperazine.
  • the present invention is based in part on the discovery that stable oral dosage forms comprising ramipril and at least one other active agent can be achieved by first pre- blending or co-milling a blending agent such as glyceryl behenate with ramipril during manufacture of oral dosage forms that contain ramipril and another active agent.
  • a blending agent such as glyceryl behenate
  • the inventors have made the surprising discovery that by combining ramipril with a blending agent such as glyceryl behenate, prior to formulation of ramipril and a diuretic into a tablet dosage form, the rate of ramipril degradant production is extremely low.
  • the inventors of the present invention believe that the blending agent such as glyceryl behenate coats the ramipril and is able to protect the ramipril from physical and environmental stress that, under normal conditions, cause the ramipril to degrade into degradant products such as ramipril-DKP and ramipril-diacid.
  • the blending agent such as glyceryl behenate
  • ramipril decomposition into degradant products such as ramipril-DKP and ramipril diacid
  • the rate of decomposition of ramipril in compositions of the invention is less than 0.05% of the total weight of ramipril on average per month for at least 36 months from the date that the ramipril compositions are first formulated.
  • the inventors have demonstrated that the ramipril in the tablets of the invention containing ramipril and chlorthalidone is as bioavailable as ramipril formulated alone [0023]
  • the pharmaceutical compositions contemplated by the present invention comprise ramipril in combination with at least one other active ingredient, wherein the ramipril has a low rate of degradation and is substantially free of ramipril-DKP and ramipril-diacid.
  • the pharmaceutical compositions of the present invention have increased stability, bioavailability and shelf-life compared to current formulations comprising ramipril alone.
  • compositions of the present invention allow ramipril to maintain potency, assuring health care providers and patients that they are giving and receiving consistent and exact treatment.
  • the invention also contemplates reducing the rate of ramipril-DKP formation, especially under formulation and extended storage conditions.
  • the present invention also relates to methods of making the pharmaceutical compositions, of the present invention. Such methods comprise first pre-blending and/or co- milling ramipril with a blending agent before combining with other active agents and excipients. The methods of the present invention also comprise first coating ramipril with a blending agent prior to formulation of ramipril into a dosage form that includes one or more additional active agents.
  • the present invention is also directed to methods of treating cardiovascular disorders such as hypertension.
  • cardiovascular disorders such as hypertension can be treated by administering to a patient in need thereof a tablet comprising an effective amount of ramipril and hydrochlorothiazide.
  • the present invention is directed to methods of treating hypertension in a patient requiring a reduction in systolic blood pressure of > 20 mm Hg or a reduction in diastolic blood pressure of > 10 mm Hg comprising orally administering to the patient a tablet comprising a therapeutically effective amount of ramipril and a therapeutically effective amount of hydrochlorothiazide.
  • the present invention is directed to methods of treating cardiovascular disorders, such as hypertension in specific patient populations such as individuals of African- American descent, males, females, and individuals 65 years and older.
  • the present invention includes methods of treating hypertension in a patient in need thereof comprising orally administering to a patient an effective amount of ramipril and an effective amount of hydrochlorothiazide, wherein response to the administration of ramipril and hydrochlorothiazide was the same of similar in an African- American and a non African- American patient.
  • the present invention also includes methods of treating hypertension in a patient in need thereof comprising administering to a patient diagnosed with hypertension or diagnosed to be at risk for hypertension a daily oral dose of 20 mg of ramipril, wherein the oral dose is administered in the from of at least two tablets, each tablet comprising 10 mg of ramipril.
  • the present invention includes methods of treating hypertension in a female in need thereof by administering to the female a tablet comprising at least 10 mg of ramipril at least twice a day and methods of treating hypertension in a patient in need thereof, wherein the patient is 65 years or older by orally administering to the patient a tablet comprising at least 10 mg of ramipril at least twice a day.
  • the present invention includes method of treating hypertension comprising orally administering to a patient in need thereof at least twice daily a tablet comprising ramipril or a pharmaceutically acceptable salt, wherein the at least twice daily administration of the tablet is more effective in lowering blood pressure as a once daily dosage form having an equivalent amount of ramipril as well as, methods for the treatment of hypertension comprising administering twice daily to a patient in need thereof a tablet comprising ramipril, wherein the increase in ambulatory trough blood pressure is less than the increase in ambulatory blood pressure when the patient is administered a once daily dosage form with the equivalent amount of ramipril.
  • the present invention is also directed to methods of reducing blood pressure in a patient.
  • the present invention includes comprising orally administering to a patient in need thereof at least twice daily a tablet comprising ramipril or a pharmaceutically acceptable salt, wherein the reduction in blood pressure of the patient is greater than the reduction of blood pressure in the patient if the patient is administered a once daily dosage form with the equivalent amount of ramipril.
  • the present invention includes methods of reducing the sitting systolic blood pressure of an individual who has a sitting systolic blood pressure between about 140 and 180 mm Hg by orally administering to the individual at least 10 mg of ramipril at least twice daily and methods of reducing the sitting diastolic blood pressure of an individual who has a sitting diastolic blood pressure between about 100 and 1 15 mm Hg by orally administering to the individual at least 10 mg of ramipril at least twice a day.
  • the present invention is also directed to methods of improving the therapeutic efficacy and/or bioavailability of ramipril in females, individuals 65 years of age or older, individuals of non- African decent, na ⁇ ve and non-na ⁇ ve individuals by administering to such individuals at least 10 mg of ramipril at least twice a day.
  • the present invention is also directed to dosing regimens wherein a total daily dose of a therapeutically effective amount of ramipril is administered to a patient in multiple daily doses such that the administration of multiple daily dosages of ramipril is more effective than a single daily dose containing an equivalent amount of ramipril.
  • This embodiment of the invention is based on the discovery that administration of multiple daily doses of ramipril was more effective in lowering blood pressure and treating hypertension than a single daily dose of ramipril containing an amount of ramipril that is equal to the amount contained in the multiple daily doses of ramipril.
  • the present invention is directed to a twice-a-day dosing regime for the treatment of hypertension comprising twice daily administration of an oral dosage form comprising 10 mg of ramipril or a pharmaceutically acceptable salt.
  • Figure 10.1 Boxplot of Change from Baseline to End of Treatment (Visit 7) in Mean Sitting Diastolic Blood Pressure (mm Hg).
  • Figure 10.2 Boxplot of Change from Baseline to End of Treatment (Visit 7) in Mean Sitting Systolic Blood Pressure (mm Hg).
  • Figure 10.3 Boxplot of Change from Baseline to End of Treatment (Visit 7) in Mean Standing Diastolic Blood Pressure (mm Hg).
  • Figure 10.4 Boxplot of Change from Baseline to End of Treatment (Visit 7) in Mean Standing Systolic Blood Pressure (mm Hg).
  • Figure 10.9 Boxplot of Change from Baseline to End of Treatment (Visit 7) in Mean Ambulatory Diastolic Blood Pressure (mm Hg).
  • FIG. 10 Figure 10.13 - Plot of Mean Ambulatory Diastolic Blood Pressure (mm Hg) at Visit 3 (Baseline) by Hour and Treatment Group.
  • Visit 3 Baseline
  • Treatment Group Visit 3
  • Figure 10.15 Plot of Mean Ambulatory Diastolic Blood Pressure (mm Hg) at Visit 7 by Hour and Treatment Group.
  • Figure 1 1.8- Plot of minimum HCTZ dissolution results for ramipril/HCTZ tablets (5/25 mg) in blisters of 10.
  • Figure 1 1.9- Plot of minimum HCTZ dissolution results for ramipril/HCTZ tablets (10/12.5 mg) in bottles of 100.
  • stabilized can encompass products that are substantially free of breakdown products or degradants.
  • degradants include, but are not limited to, ramipril-diacid and ramipril-DKP.
  • substantially free refers to the ramipril formulations described herein that have significantly reduced levels of detectable breakdown products; e.g., ramipril- diacid and/or ramipril-DKP.
  • cardiac disorder(s) as used herein means and broadly encompasses any disease, illness, sickness, disorder, condition, symptom or issue involving or concerning any part or portion of the heart or blood vessels of an animal, including a human.
  • blood vessel as used herein, is defined to include any vessel in which blood circulates.
  • cardiovascular disorders include, for example, arterial enlargements, arterial narrowings, peripheral artery disease, atherosclerotic cardiovascular disease, high blood pressure, angina, irregular heart rates, inappropriate rapid heart rate, inappropriate slow heart rate, angina pectoris, heart attack, myocardial infarction, transient ischemic attacks, heart enlargement, heart failure, congested heart failure, heart muscle weakness, inflammation of the heart muscle, overall heart pumping weakness, heart valve leaks, heart valve stenosis (failure-to-open fully), infection of the heart valve leaflets, heart stoppage, asymptomatic left ventricular dysfunction, cerebrovascular incidents, strokes, chronic renal insufficiency, and diabetic or hypertensive nephropathy.
  • These above-listed conditions commonly arise in healthy, pre-disposed or critically ill patients, and may or may not be accompanied by hypertension, angina, light-headedness, dizziness, fatigue or other symptoms.
  • treat(s) are used herein interchangeably and refer to any treatment of a disorder in an animal diagnosed or inflicted with such disorder and includes, but is not limited to: (a) caring for an animal diagnosed or inflicted with a disorder; (b) curing or healing an animal diagnosed or inflicted with a disorder; (c) causing regression of a disorder in an animal; (d) arresting further development or progression of a disorder in an animal; (e) slowing the course of a disorder in an animal; (f) relieving, improving, decreasing or stopping the conditions of a disorder in a animal; (g) relieving, decreasing or stopping the symptoms caused by or associated with a disorder in an animal; or (h) reducing the frequency, number or severity of episodes caused by or associated with a disorder in an animal.
  • prevent(s) means any prevention or any contribution to the prevention of a disorder in an animal or the development of a disorder if none has occurred in an animal which may be predisposed to such disorder but has not yet been inflicted with or diagnosed as having such disorder.
  • safe and effective amount(s) means any amount of a drug which, when administered to a subject to be treated, will achieve a beneficial pharmacological effect or therapeutic improvement consistent with the objectives of the present invention without causing serious, adverse or otherwise treatment-limiting side effects (at a reasonable benefit/risk ratio), within the scope of sound medical judgment.
  • the term “about” as used herein means approximately or near or around.
  • the term “about” indicates that the dosage amount or range specified is an approximate dosage amount or range and that it includes not only the amount or range actually specified, but those amounts or ranges that may also be safe and effective amounts that are somewhat outside the cited amount or range.
  • pharmaceutically acceptable salt refers to a salt that retains the biological effectiveness of the free acid and/or base of the specified compound.
  • pharmaceutically acceptable salts include sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, phosphates, monohydrogenphosphates, dihydrogenphosphates, metaphosphates, pyrophosphates, chlorides, bromides, iodides, acetates, propionates, decanoates, caprylates, acrylates, formates, isobutyrates, caproates, heptanoates, propiolates, oxalates, malonates, succinates, suberates, sebacates, fumarates, maleates, butyne-l,4-dioates, hexyne-l,6-dioates, benzoates, chlorobenzoates, methylbenzoates, dinitrobenzoates, hydroxybenzo
  • compositions of the present invention relate to compositions comprising a combination of two or more drugs wherein at least one of the drugs is susceptible to degradation when exposed to the environment or exposed to physical stresses during the manufacturing process and wherein the rate of degradation of the compound is extremely low.
  • the present invention encompasses pharmaceutical compositions that comprise a combination of two or more drugs wherein at least one of the drugs is susceptible to degradation when exposed to the environment or exposed to physical stresses during the manufacturing process; and a blending agent.
  • the drug susceptible to degradation is an
  • ACE inhibitor Suitable ACE inhibitors include, but are not limited to, captopril, benazepril, enalapril, lisinopril, fosinopril, ramipril, perindopril, quinapril, moexipril, and trandolapril.
  • captopril benazepril
  • enalapril lisinopril
  • fosinopril ramipril
  • perindopril ramipril
  • quinapril moexipril
  • trandolapril trandolapril.
  • ramipril its derivatives and salts are of special interest.
  • Suitable ramipril derivatives and salts include, but are not limited to, the esters and those common salts known to be substantially equivalent to ramipril.
  • Suitable ramipril esters include, but are not limited to, hexahydroramipril, ramipril benzyl ester, isopropyl ester, ethyl ester or methyl ester.
  • Pharmaceutically acceptable salts of ramipril include, but are not limited to, salts with pharmaceutically acceptable amines or inorganic or organic acids such as, HCl, HBr, H 2 SO 4 , maleic acid, fumaric acid, tartaric acid and citric acid.
  • Ramipril is a 2-aza-bicyclo [3.3.0]-octane-3-carboxylic acid derivative with five chiral centers, and 32 different enantiomeric forms.
  • the chemical name of ramipril is (2S,3aS,6aS)-l [(S)-N-[(S)-l-carboxy-3-phenylpropyl]alanyl]octahydrocyclo-penta[b]pyrrole- 2-carboxylic acid, 1 -ethyl ester is most preferred and has the following chemical structure:
  • Ramipril is converted to ramiprilat in the body by hepatic cleavage of the ester group.
  • Ramiprilat the diacid or free acid metabolite of ramipril, is obtained in vivo upon administration of ramipril but ramiprilat is not absorbed appreciably in- vivo from the GI tract.
  • the percent of ramiprilat does not exceed 20% after 8 weeks at 40°C and 75% relative humidity.
  • the percent of ramiprilat does not exceed 1.0% during the life of the composition.
  • the percent of ramiprilat does not exceed 0.5% during the life of the composition.
  • Ramipril is marketed in the United States under the brand name Altace® and abroad under the brand name Delix®.
  • Altace® ramipril
  • Ramipril compositions of the present invention can be formulated with any form of ramipril known in the art.
  • Ramipril suitable for the present invention can be uncoated or be coated with a coat forming material.
  • Ramipril and processes for making and using ramipril are described and claimed in U.S. Patent Nos. 4,587,258, 5,061,722 and 5,403,856, all of which are incorporated herein by reference in their entirety.
  • the preparation of ramipril has also been described in EP 0 079 022 A2, EP 0 317 878 Al and DE 44 20 102 A, which are incorporated herein by reference in their entirety.
  • Uncoated ramipril suitable for the present invention includes ramipril.
  • Coated ramipril suitable for the present invention can be any coated ramipril known in the art.
  • coated ramipril suitable for the present invention can include ramipril particles that are coated with a suitable coat forming material.
  • Coated ramipril suitable for the present invention can be partially, substantially or completely covered with a coat forming material.
  • Ramipril particles can include but are not limited to, coated ramipril micro- or nanoparticles, coated ramipril crystalline particles, coated individual ramipril crystals and coated ramipril agglomerates, granules or beads.
  • compositions of the present invention can also contain anhydrous, pharmaceutical grade ramipril powder comprising coated ramipril particles.
  • the pharmaceutical compositions of the present invention comprise ramipril in combination with at least one other active agent, wherein the ramipril is substantially stable against decomposition into degradant products, such as ramipril-diacid and ramipril-DKP.
  • the ramipril compositions of the present invention have improved stability and shelf-life. This improved stability allows the ramipril compositions to maintain potency and improve effectiveness and bioavailability of ramipril compared to other ramipril formulations.
  • non-limiting examples of the active agents that can be formulated in combination with ramipril include: diuretics such as but not limited to chlorthalidone, furosemide, bumetanide, torsemide, hydrochlorothiazide, metolazone, and spironolactone; angiotensin receptor blockers such as but not limited to candesartan, eprosartan, irbesartan, telmisartan, valsartan and losartan; other ACE inhibitors such as but not limited to captopril, benazepril, enalapril, lisinopril, fosinopril, perindopril, quinapril, moexipril and trandolapril; cholesterol lowering drugs such as but not limited to atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin and simva
  • diuretics such as but not limited to chlor
  • the diuretics contemplated in the present invention are chlorthalidone and/or hydrochlorthiazide.
  • Chlorthalidone is a monosulfamyl diuretic that differs chemically from thiazide diuretics in that a double ring system is incorporated in its structure. It is 2-chloro-5- (l-hydroxy-3-oxo-l-isoindolinyl) benzenesulfonamide with an molecular formula of Ci 4 H I iClN 2 O 4 S, a molecular weight of 338.76 and the following structural formula:
  • Hydrochlorothiazide is a diuretic and antihypertensive. It is the 3, 4-dihydro derivative of chlorothiazide. Its chemical name is 6-chloro-3, 4-dihydro-2H-l, 2, 4- benzothiadiazine-7-sulfonamide 1, 1 -dioxide. Its empirical formula is C 7 H 8 ClN 3 O 4 S 2 and its structural formula is:
  • a therapeutically effective amount of hydrochlorothiazide can be formulated into a dosage form such as a tablet suitable for once-a-day or twice-a-day dosing.
  • the compositions comprise ramipril and a diuretic, wherein the bioavailability of the ramipril is the same as the bioavailability of ramipril when formulated alone.
  • the potency and stability of ramipril is improved when compared to current ramipril formulations.
  • the bioavailability or potency of the diuretic is improved or the same when compared to current single agent diuretic formulations. 6.2.3 Stability of the ACE Inhibitor
  • the rate of decomposition of ramipril to ramipril-DKP is typically monitored at conditions of 25 0 C and 60% relative humidity (R.H.). These conditions may also be described as room temperature conditions.
  • the rate of decomposition of ramipril to ramipril- DKP, in the compositions of the present invention is between 0.00-0.12% of the total weight of ramipril per month.
  • the rate of decomposition of ramipril in the compositions of the present invention is 0.00-0.1 1 % of the total weight of ramipril; more preferably the rate of decomposition is 0.04-0.095% of the total weight of ramipril per month.
  • the ramipril compositions of the present invention result in ramipril-DKP formation of between about 0.0-0.6 % or 0.0-0.6 % of the total weight of ramipril during about the first three months or the first three months after the compositions are formed and between about 0-4 % or 0-4% of the total weight of ramipril during a period of at least about 36 months or 36 months after the composition are formed.
  • the pharmaceutical compositions of the present invention have a rate of decomposition of ramipril of less than about 0.04% to about 0.095% of the total weight of ramipril at room temperature or less than 0.04% to 0.095% of the total weight of ramipril at room temperature, on average per month for at least about 36 months or at least 36 months from the date that the ramipril compositions are first formulated.
  • Preferred pharmaceutical compositions have ramipril-DKP formation of less than about 0.04% to about 0.085% or less than 0.04% to 0.085% of the total weight of ramipril at room temperature, on average per month for an extended period, more preferred the pharmaceutical compositions have ramipril-DKP formation of less than about 0.04% to about 0.055% or less than 0.04% to 0.055% of the total weight of ramipril at room temperature, per month on average for such an extended period, and even more preferred pharmaceutical compositions have ramipril-DKP formation of less than about 0.04% to about 0. 042% or less than 0.04% to 0.042% of the total weight of ramipril at room temperature, per month on average for an extended period of time.
  • compositions of the present invention result in ramipril-DKP formation of less than about 0.4% or less than 0.4% during about the first three months of the total weight of ramipril and less than about 2.0% or less than 2.0% of the total weight of ramipril during a period of at least about 36 months after the first three month period.
  • ramipril-DKP formation less than about 0.4% or less than 0.4% of the total weight of ramipril during about the first three months and less than about
  • compositions of the present invention result in ramipril-
  • compositions result in ramipril-DKP formation of less than about 0.3% or less than
  • compositions of the present invention comprise ramipril alone or in combination with at least one other active agent, wherein the rate ramipril decomposition to ramipril-DKP, is less than about 0.4% or less than 0.4% of the total weight of the ramipril during about the first three months after the compositions are formed.
  • compositions of the present invention comprise ramipril alone or in combination with at least one other active agent, wherein the rate ramipril decomposition to ramipril-DKP, is less than about 0.3% or less than 0.3% of the total weight of the ramipril during about the first three months after the compositions are formed.
  • compositions of the present invention comprise ramipril in combination with at least one other active agent, wherein the rate of ramipril decomposition to ramipril-DKP, is less than about 0.75% or less than 0.75% of the total weight of the ramipril during about the first 6 months after the compositions are formed.
  • compositions of the present invention comprise ramipril in combination with at least one other active agent, wherein the rate of ramipril decomposition to ramipril-DKP, is less than about 3.0% or less than 3.0% of the total weight of the ramipril during about the first 36 months after the compositions are formed.
  • the active agent formulated in combination with ramipril is preferably a diuretic.
  • the bioavailability and/or potency and stability of the diuretic is the same or improved when compared to single agent formulations.
  • the active agent formulated in combination with ramipril is hydrochlorothiazide.
  • the ramipril/ hydrochlorothiazide combination is formulated in the form of a tablet.
  • the ramipril/ hydrochlorothiazide tablet can be formulated for once-a-day dosing.
  • once-a-day dosing is preferred due to the fact that a once-a-day dosing regimen is easier for a patient to take as compared with dosage forms that must be administered more than once daily, which leads to increased patient compliance.
  • An example of a once-a-day tablet comprising ramipril and hydrochlorothiazide is a tablet that comprises 20 mg of ramipril and 12.5 mg or 25 mg of hydrochlorothiazide.
  • the ramipril/ hydrochlorothiazide tablet can be formulated for twice-a-day dosing. In certain instances twice-a-day dosing is preferred should the twice-a-day dosing regimen lead to increase bioavailability of the combination therapy.
  • An example of a twice-a-day tablet comprising ramipril and hydrochlorothiazide is a tablet that comprises 10 mg of ramipril and 12.5 mg or 25 mg of hydrochlorothiazide.
  • the tablet for once-a-day dosing comprising 10 mg of ramipril and 12.5 mg or 25 mg of HCTZ is bioequivalent to one 10 mg tablet or capsule of ramipril co-administered with one tablet or capsule of 12.5 mg or 25 mg of HCTZ once a day.
  • the tablet for twice-a-day dosing comprising
  • 10 mg of ramipril and 12.5 mg or 25 mg of HCTZ is bioequivalent to one 10 mg tablet or capsule of ramipril co-administered with one tablet or capsule of 12.5 mg or 25 mg of HCTZ twice a day.
  • the dosage forms of the present invention can be administered to a patient for the treatment of cardiovascular disorders.
  • Cardiovascular disorders can include, but are not limited to, hypertension, heart failure, congestive heart failure, myocardial infarction, atherosclerotic cardiovascular disease, asymptomatic left ventricular dysfunction, chronic renal insufficiency, and diabetic or hypertensive nephropathy.
  • the dosage forms of the present invention can be administered to a patient for the treatment of hypertension.
  • the present invention is directed to methods of treating hypertension comprising administering to a patient in need thereof a tablet comprising ramipril and hydrochlorothiazide.
  • the tablet includes 2.5 mg to 20 mg of ramipril and 12.5 mg or 25 mg of hydrochlorothiazide and is administered once-a-day. In certain embodiments, the tablet includes 2.5 mg to 10 mg of ramipril and 12.5 mg of hydrochlorothiazide and is administered twice-a-day. In certain embodiments, the tablet includes 10 mg of ramipril and 12.5 mg of hydrochlorothiazide and is administered twice-a-day. In other embodiments, the tablet includes 20 mg of ramipril and 25 mg of hydrochlorothiazide and is administered once-a-day.
  • the present invention also includes, methods of treating hypertension comprising orally administering to a patient in need thereof a once daily tablet comprising a therapeutically effective amount of ramipril and a therapeutically effective amount hydrochlorothiazide, wherein the once daily tablet is at least as effective in lowering diastolic blood pressure when compared to a twice a day dosage form having equivalent amounts of ramipril and hydrochlorothiazide.
  • the present invention includes methods of treating hypertension in a patient in need thereof comprising administering to a patient diagnosed with hypertension or diagnosed to be at risk for hypertension a daily oral dose of no more than 20 mg of ramipril and no more than 25 mg of hydrochlorothiazide, wherein the dosage form contains both ramipril and hydrochlorothiazide.
  • the 20 mg of ramipril can be administered in one dose or, alternatively, in more than one dose, so that no more than 20 mg of ramipril is administered to the patient.
  • the 25 mg of hydrochlorothiazide can be administered in one dose or, alternatively, in more than one dose, so that no more than 25 mg of hydrochlorothiazide is administered to the patient.
  • the daily dose of 20 mg of ramipril and the daily dose of 25 mg of hydrochlorothiazide can be administered to the patient in one dose over a period of 24 hours or the daily dose of 20 mg of ramipril and the daily dose of 25 mg of hydrochlorothiazide can be administered to the patient in two doses over a period of 24 hours.
  • the total daily dose of 20 mg of ramipril and the total daily dose of 25 mg of hydrochlorothiazide is administered to the patient in multiple doses over a period of 24 hours.
  • the daily dose of 20 mg of ramipril and the daily dose of 25 mg of hydrochlorothiazide can be administered in two, three, four, five, six, seven or eight times a day.
  • a dose of ramipril and hydrochlorothiazide can be administered hourly, every 2, 4, 6, 8 or 12 hours until the daily dose of 20 mg of ramipril and the daily dose of 25 mg of hydrochlorothiazide has been administered.
  • Such tablets can contain 2.5 mg of ramipril and 12.5 mg of hydrochlorothiazide, 5 mg of ramipril and 12.5 mg of hydrochlorothiazide, 5 mg of ramipril and 25 mg of hydrochlorothiazide, 10 mg of ramipril and 12.5 or 25 mg of hydrochlorothiazide or 20 mg of ramipril and 12.5 or 25 mg of hydrochlorothiazide.
  • the present invention is also directed to treatment of hypertension in certain patient populations.
  • the present invention is directed to methods of treating hypertension in a patient requiring a reduction in systolic blood pressure of > 20 mm Hg or a reduction in diastolic blood pressure of > 10 mm Hg comprising orally administering to the patient a tablet comprising an effective amount of ramipril and an effective amount of hydrochlorothiazide.
  • the present invention includes methods of treating hypertension in a patient in need thereof comprising orally administering to a patient an effective amount of ramipril and an effective amount of hydrochlorothiazide, wherein response to the administration of ramipril and hydrochlorothiazide was the same or similar in an individual of African descent and an individual of non- African descent.
  • the present invention is also directed to methods of reducing blood pressure in a patient.
  • the present invention includes methods of reducing blood pressure comprising administering to a patient in need thereof a tablet comprising a therapeutically effective amount of ramipril and a therapeutically effective amount hydrochlorothiazide, wherein the reduction in blood pressure of the patient is greater than the reduction of blood pressure in the patient if the patient is administered an equivalent of ramipril or hydrochlorothiazide alone.
  • the present invention is directed to methods of treating hypertension comprising administering to a patient in need thereof a dosage form comprising ramipril alone.
  • a dosage form comprising ramipril alone.
  • the inventors have shown that administration of 20 mg of ramipril in either a once-a-day dosage form or a twice-a-day dosage from lowers the blood pressure of an individual with Stage 2 essential hypertension.
  • the present invention is directed to methods of treating hypertension comprising administering to a patient in need thereof a dosage form comprising ramipril alone, wherein the dosage form is administered at least twice daily and is at least as effective and in some cases more effective than the administration of an equivalent amount of ramipril once daily.
  • the dosage form includes 10 mg of ramipril in the form of a tablet and is administered twice-a-day.
  • the present invention also includes, methods of treating hypertension comprising orally administering to a patient in need thereof a twice daily dosage form comprising ramipril, wherein the twice daily dosage form of ramipril is at least as effective in lowering the sitting systolic or diastolic or both the sitting systolic and diastolic blood pressure when compared to a once-a-day dosage forms having an equivalent amount of ramipril.
  • the present invention includes methods of treating hypertension in a patient in need thereof comprising administering to a patient diagnosed with hypertension or diagnosed to be at risk for hypertension a daily oral dose of no more than 20 mg of ramipril.
  • the 20 mg of ramipril can be administered in one dose or, alternatively, in more than one dose, so that no more than 20 mg of ramipril is administered to the patient.
  • the daily dose of 20 mg of ramipril can be administered to the patient in two doses over a period of 24 hours.
  • the total daily dose of 20 mg of ramipril is administered to the patient in multiple doses over a period of 24 hours.
  • the daily dose of 20 mg of ramipril can be administered in one, two, three, four, five, six, seven or eight times a day.
  • a dose of ramipril can be administered hourly or every 2, 4, 6, 8 or 12 hours until the daily dose of 20 mg of ramipril has been administered.
  • the dosage form of ramipril can be administered as a tablet, capsule or caplet and such dosage forms can contain 1.25 mg, 2.5 mg, 5 mg, 10 mg or 20 mg of ramipril.
  • the dosage form is a tablet such tablets can contain 1.25 mg, 2.5 mg, 5 mg, 10 mg or 20 mg of ramipril.
  • the present invention is directed to methods of treating hypertension comprising administering to a patient in need thereof a tablet comprising ramipril.
  • the tablet includes 10 mg of ramipril and is administered twice-a-day.
  • the tablet includes 20 mg of ramipril and is administered once-a-day.
  • the present invention also includes, methods of treating hypertension comprising orally administering to a patient in need thereof a twice daily tablet comprising ramipril, wherein the twice daily tablet of ramipril is at least as effective in lowering the systolic or diastolic or both the systolic and diastolic blood pressure when compared to a once-a-day dosage form having an equivalent amount of ramipril.
  • the present invention includes methods of reducing blood pressure in a patient.
  • Such methods include orally administering to a patient in need thereof at least twice daily a tablet comprising ramipril or a pharmaceutically acceptable salt, wherein the reduction in blood pressure of the patient is greater than the reduction of blood pressure in the patient if the patient is administered a once daily dosage form with the equivalent amount of ramipril.
  • the present invention includes methods of reducing the sitting systolic blood pressure of an individual who has a sitting systolic blood pressure between about 140 and 180 mm Hg by orally administering to the individual at least 10 mg of ramipril at least twice daily and methods of reducing the sitting diastolic blood pressure of an individual who has a sitting diastolic blood pressure between about 100 and 115 mm Hg by orally administering to the individual at least 10 mg of ramipril at least twice a day.
  • the present invention is directed to methods of treating hypertension in a patient in need thereof comprising administering to a patient diagnosed with hypertension or diagnosed to be at risk for hypertension a daily oral dose of 20 mg of ramipril, wherein the oral dose is administered in the from of at least two tablets, each tablet comprising 10 mg of ramipril.
  • the present invention includes methods of treating hypertension in a female in need thereof by administering to the female at least 10 mg of ramipril at least twice a day and methods of treating hypertension in a patient in need thereof, wherein the patient is 65 years or older by orally administering to the patient at least 10 mg of ramipril at least twice a day.
  • the present invention includes methods of treating hypertension comprising orally administering to a patient in need thereof at least twice daily a tablet comprising ramipril or a pharmaceutically acceptable salt, wherein the at least twice daily administration of the tablet is more effective in lowering blood pressure as a once daily dosage form having an equivalent amount of ramipril.
  • the present invention also includes methods for the treatment of hypertension comprising administering twice daily to a patient in need thereof a tablet comprising ramipril, wherein the increase in ambulatory trough blood pressure is less than the increase in ambulatory trough blood pressure when the patient is administered a once daily dosage form with the equivalent amount of ramipril.
  • Patient populations include individuals who have been diagnosed with hypertension or who have been diagnosed with the risk of developing hypertension, females, individuals 65 years of age or older, individuals of non- African descent, naive individuals and non-na ⁇ ve individuals.
  • the present invention is directed to methods of improving the efficacy and/or bioavailability of ramipril in females, individuals 65 years of age or older, individuals of non- African descent, naive individuals and non-na ⁇ ve individuals by administering to such individuals at least 10 mg of ramipril at least twice a day.
  • such females, individuals 65 years of age or older, individuals of non- African descent, na ⁇ ve individuals and non-na ⁇ ve individuals can be diagnosed with hypertension or be diagnosed to be at risk of developing hypertension.
  • the present invention includes methods of lowering the 24-hour mean systolic and diastolic of an individual who has been diagnosed with hypertension or who is at risk of being diagnosed with hypertension by administering to the individual a once-a-day dose of 20 mg of ramipril.
  • the once-a-day dose of 20 mg of ramipril can be in the form of a tablet.
  • the 24-hour mean systolic and diastolic blood pressure can be measured using a 24-hour ambulatory blood pressure monitor.
  • compositions described herein can also include at least one pharmaceutically acceptable excipient. Suitable are described in the paragraphs below.
  • the blending agent in each of the compositions of the invention can be any substance suitable for pre-blending and co-milling, which stabilizes the drug and significantly reduces the degradation of the drug.
  • the phrase "blending agent" is interchangeable with "blending compound”.
  • the blending agent can coat the ramipril and reduce the degradation rate.
  • Blending agents contemplated by the present invention include polymers, starches, stearates, silicas, waxes (atomized glyceryl palmitostearate, dioctyl sodium sulphosuccinate), surfactants, and fatty acids (preferably having a chain length of eight carbons or greater which may contain one or more double bonds).
  • blending agents suitable for the present invention include, but are not limited to, include long chain fatty acid-containing glycerol esters.
  • Blending agents include, but are not limited to, glyceryl behenate, glyceryl stearate, stearyl alcohol, magnesium stearate, macrogol stearate ether, palmitosearate, ethylene glycol, polyethylene glycol, ethylene oxide polymers, sodium lauryl sulfate, magnesium lauryl sulfate, sodium oleate, sodium stearyl fumerate, leucine, stearic acid, cetyl alcohol, lauryl alcohol, amylopectin, poloxymer or combinations thereof. Most preferably, the blending agent is glyceryl behenate.
  • the blending agent can be present from at least about 0.1 wt% or from at least about 0.1 wt% and above by weight of the total composition.
  • the blending agent is present at about 0.5 wt. % and above or 0.5 wt. % and above.
  • the blending agent is present at about 1.0 wt. % and above or 1.0 wt. % and above.
  • the blending agent is present at about 2.0 wt. % and above or 2.0 wt. % and above.
  • the blending agent is present at about 3.0 wt. % and above or 3.0 wt. % and above.
  • the blending agent is present at about 4 wt. % and above (e.g., 5 and 10 wt.%).
  • the blending agent can be present in a ratio of about 1 : 10 to about 10:1 or in a ratio of 1 : 10 to 10: 1 of the drug.
  • the blending agent can be present in a ratio of about 1 :5 to about 5:1 or in a ratio of 1 :5 to 5: 1 or about 1 :2 or 2:1 or in a ratio of 1 :2 to 2:1 of the drug.
  • the pharmaceutical compositions of the present invention comprise ramipril and a blending agent in combination with at least one other active agent, wherein ramipril is coated by the blending agent.
  • ramipril can be substantially coated by the blending agent.
  • the ramipril is substantially coated when the blending agent coats ramipril wherein ramipril has a low or no rate of degradation.
  • the ramipril can be between about 50% to 100% or between 50% to 100% coated by the blending agent.
  • the ramipril is between about 75% to 100% or between 75% to 100% coated by the blending agent or more preferably between about 85% to 100% or between 85% to 100% coated by the blending agent.
  • the ramipril is between about 95% to 100% or between 95% to 100% coated by the blending agent.
  • compositions of the present invention may also include pharmaceutically acceptable additives into any suitable type of unit dosage form.
  • suitable additives include, but are not limited to, diluents, binders, vehicles, carriers, excipients, binders, disintegrating agents, lubricants, swelling agents, solubilizing agents, wicking agents, cooling agents, preservatives, stabilizers, sweeteners, flavors, polymers etc. While any pharmaceutically acceptable additive is contemplated by the present invention, it should be understood that the additive(s) selected for compounding with coated ramipril particles should not defeat the stability objectives of the present invention.
  • additives may be suitable for the present invention so long as such additives do not cause ramipril, as it is combined with a blending agent, to degrade. Moreover, in certain preferred embodiments, such additives also will not affect the bioavailability of the other active agent formulated in combination with ramipril.
  • excipients include, but are not limited to, acacia, alginic acid, croscarmellose, gelatin, gelatin hydrosylate, mannitol, plasdone, sodium starch glycolate, sorbitol, sucrose, and xylitol.
  • suitable excipients include amorphous lactose, beta lactose, microcrystalline cellulose, croscarmellose sodium, dicalcium phosphate, carboxymethyl cellulose, hydroxypropyl cellulose, polyethylene gylcols, sodium lauryl sulfate, and the like.
  • additional stabilizers or preservatives include, but are not limited to, parahydroxybenzoic acid alkyl esters, antioxidants, antifungal agents, and other stabilizers/preservatives known in the art.
  • coloring agents include, but are not limited to, water soluble dyes, Aluminum Lake, ion oxide, natural colors, titanium oxide, red ferric oxide, yellow ferric oxide and the like.
  • Examples of diluents or fillers include, but are not limited to, water-soluble and/or water-insoluble tabletting fillers.
  • the water-soluble diluent agent may be constituted from a polyol of less than 13 carbon atoms, in the form of directly compressible material (the mean particle size being between about 100 and about 500 microns or between 100 and 500 microns), in the form of a powder (the mean particle size being less than about 100 microns or less than 100 microns) or a mixture thereof.
  • the polyol is preferably chosen from the group comprising of mannitol, xylitol, sorbitol and maltitol.
  • the water-insoluble diluent agent may be a cellulosic derivative, such as, microcrystalline cellulose or a starch, such as, pregelatinized starch. Especially preferred diluents are those with minimal moisture content, such as lactose monohydrate and magnesium oxide.
  • disintegrating agents include, but are not limited to, cross-linked sodium carboxymethylcellulose, crospovidone and their mixtures. A part of the disintegrating agent may be used for the preparation of PPI, cholinergic agonist, parietal activator and/or antacid granules.
  • lubricating agents include, but are not limited to, magnesium stearate, stearic acid and its pharmaceutically acceptable alkali metal salts, sodium stearyl fumarate, Macrogol 6000, glyceryl behenate, talc, colloidal silicon dioxide, calcium stearate, sodium stearate, Cab-O-Sil, Syloid, sodium lauryl sulfate, sodium chloride, magnesium lauryl sulfate, talc and their mixtures.
  • a portion of the lubricant may be used as an internal solid lubricant which is blended and granulated with other components of the granulation.
  • Lubricating agents and blending agents can comprise of the same material, e.g. glycerol behenate, however, as a lubricating agent the material does not act to stabilize the active agent.
  • swelling agents include, but are not limited to, starches; polymers; cellulosic materials, such as, microcrystalline cellulose, hydroxypropylmethyl cellulose, sodium carboxymethylcellulose and ethyl cellulose; waxes such as bees wax; natural materials, such as, gums and gelatins; or mixtures of any of the above.
  • Examples of polymers include, but are not limited to, polysaccharides, celluloses, and organic moieties such as polyvinyl pyrrolidines and plastics.
  • Examples of celluloses include, but are not limited to, hydroxypropylcellulose, hydroxypropylmethylcellulose, hydroxylpropyl-methylcellulose, hydroxyethylcellulose, ethylcellulose, cellulose acetate phthalate, cellulose acetate, polyvinyl acetate phthalate, polyvinylpyrrolidone, gelatin, hydroxypropyl methyl cellulose acetate succinate, hydroxypropyl methyl cellulose succinate, hydroxylpropyl cellulose acetate succinate, hydroxyethyl methyl cellulose succinate, hydroxyethyl cellulose acetate succinate, hydroxypropyl methyl cellulose phthalate, hydroxethyl methyl cellulose acetate succinate, hydroxyethyl methyl cellulose acetate phthalate
  • exemplary commercial grades of such copolymers include the EUDRAGIT® series, which are copolymers of methacrylates, acrylates, carboxylic acid-functionalized vinyl polymers, such as the carboxylic acid functionalized polymethacrylates and carboxylic acid functionalized polyacrylates, amine-functionalized polyacrylates and polymethacrylates; proteins such as gelatin and albumin, and carboxylic acid functionalized starches such as starch glycolate, carboxylic acid functionalized polymethyacrylates, carboxylic acid functionalized polyacrylate, amine-functionalized polyacrylates, amine-functionalized polymethacrylates, proteins, carboxylic acid functionalized starches, vinyl polymers and copolymers having at least one substituent selected from the group consisting of hydroxyl, alkylacyloxy, and cyclicamido; polyvinyl alcohols that have at least a portion
  • the flavoring maybe advantageously chosen to give a combination of fast onset and long-lasting sweet taste and get a "round feeling" in the mouth with different textures or additives. Cooling agents can also be added in order to improve the mouth feeling and provide a synergy with flavors and sweetness.
  • Various other materials may be present as coatings or to otherwise modify the physical form of the dosage unit. For instance, tablets or capsules may be coated with shellac, sugar or both.
  • adjuvants which may be incorporated in the tablets include, but are not limited to, a binder such as gum tragacanth (arabic), acacia, corn starch, potato starch, alginic acid, povidone, acacia, alginic acid, ethylcellulose, methylcellulose, microcrystalline cellulose, a derivatized cellulose, such as carboxymethyl cellulose, sodium carboxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl methylcellulose, and hydroxypropyl cellulose, dextrin, gelatin, glucose, guar gum, hydrogenated vegetable oil, type I, polyethylene glycol, lactose, lactose monohydrate, compressible sugars, sorbitol, mannitol, dicalcium phosphate dihydrate, tricalcium phosphate, calcium sulfate dihydrate, maltodextrins, lactitol, magnesium carbonate, xylitol, magnesium aluminum silicate
  • a binder
  • the dosage forms of the present invention can include ramipril; hydrochlorothiazide; fillers such as hypromellose, calcium sulfate dehydrate, pregelatinized starch, microcrystalline cellulose or a combination thereof; blending agents or lubricating agents such as, sodium stearyl fumarate, sodium hydrogen carbonate; and coloring agents such as red ferric oxide and yellow ferric oxide or a combination thereof. It is apparent to one of ordinary skill in the art that any of the previously mentioned excipients can be replaced with another excipient.
  • the tablets of the present invention can contain about
  • a tablet in accordance with the present invention can include ramipril (1.9% w/w), hydrochlorothiazide (9.6% w/w), pregelatinized starch (15.0% w/w), sodium stearyl fumarate (1.0% w/w), calcium sulfate dehydrate (Compactrol)(70.5% w/w) and sodium hydrogen carbonate (1.9% w/w).
  • compositions of the present invention can be administered orally or internally to subjects. This can be accomplished, for example, by administering to the subject a solid or liquid oral dosage form by mouth or via a gastric feeding tube, a duodenal feeding tube, a nasogastric (ng) tube, a gastrostomy, or other indwelling tubes placed in the GI tract.
  • a gastric feeding tube a duodenal feeding tube
  • a nasogastric (ng) tube a gastrostomy, or other indwelling tubes placed in the GI tract.
  • Other forms of the drug may be in suppositories, suspensions, liquids, powders, creams, transdermal patches, and depots.
  • Oral pharmaceutical compositions of the present invention are generally in the form of individualized or multi unit doses, such as tablets, caplets, powders, suspension tablets, chewable tablets, rapid melt tablets, capsules, e.g., a single or double shell gelatin capsule, tablet-filled capsules, effervescent powders, effervescent tablets, pellets, granules, liquids, solutions, or suspensions, respectively.
  • Suitable tablets include, but are not limited to coated tablets, uncoated tablets, sustained release tablets, delayed release tablets, modified release tablets or immediate release tablets.
  • the tablets are designed to disintegrate in the stomach or intestine.
  • the tablets are orally disintegrating tablets (ODT).
  • the present invention contemplates any solid dosage form suitable for oral administration, ramipril tablets, capsules, tablet-filled capsules and caplets are especially preferred.
  • the pharmaceutical compositions of the present invention are formed into tablets or caplets, it is to be understood that the tablets or caplets may be scored, and that they may be of any suitable shape and size, such as round, square, rectangular, oval, diamond, pentagon, hexagon or triangular, so long as the objectives of the present invention are not defeated. It is to be further understood that when tablet-filled capsules are selected, the tablets utilized therewith may be formed into shapes that either (a) correspond to the capsules to permit over-coating or encapsulation via the capsules or (b) readily fit inside the capsules.
  • the oral pharmaceutical compositions may contain a drug in any therapeutically effective amount, such as from about 0.001 mg or from 0.001 mg or less to about 200 mg or less than 200 mg or more, or preferably from about 0.01 mg to about 100 mg or from 0.01 mg to 100 mg or preferably from about 0.1 mg to about 50 mg or from 0.1 mg to 50 mg.
  • the dosage range will be between about 1.25 mg to about 25 mg per patient per day or 1.25 mg to 25 mg per patient per day; more preferably about 10 mg to about 20 mg per patient per day or 10 mg to 20 mg per patient per day, and most preferably about 10 mg or 20 mg per day or 10 mg or 20 mg per day.
  • a particularly preferred stabilized oral unit dose or composition of the present invention may contain ramipril in a dosage amount of about 1.25 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, 12.5 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 40 mg, about 50 mg, about 60 mg, about 70 mg, about 75 mg, about 80 mg, about 90 mg, or about 100 mg or 1.25 mg, 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg, 20 mg, 25 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 75 mg, 80 mg, 90 mg, or 100 mg.
  • a particular unit dosage form and amount can be selected to accommodate the desired frequency of administration used to achieve a specified daily dosage and therapeutic effect.
  • oral dosage forms that comprise stabilized ramipril having 1.25, 2.5, 5, 10, 15 and 20 mg ramipril per unit dosage form.
  • Such dosage forms can be tablets, caplets, capsules or tablet-filled capsules.
  • oral dosage forms that comprise stabilized ramipril and chlorthalidone having 6.5, 12.5, and 25 mg chlorthalidone per unit dosage form.
  • oral dosage forms that comprise stabilized ramipril and hydrochlorothiazide having 6.5, 12.5 and 25 mg hydrochlorothiazide per unit dosage form.
  • the dosage forms of the present invention can include 2.5 mg of ramipril and 12.5 mg of hydrochlorothiazide, 5 mg of ramipril and 12.5 mg of hydrochlorothiazide, 5 mg of ramipril and 25 mg of hydrochlorothiazide, 10 mg of ramipril and 12.5 mg of hydrochlorothiazide, 10 mg of ramipril and 25 mg of hydrochlorothiazide and 20 mg of ramipril and 25 mg of hydrochlorothiazide.
  • the dosage forms of the instant invention may be administered to individuals on a regimen of one, two or more doses per day, at any time of the day.
  • the present invention also includes dosing regimens wherein a total daily dose of a therapeutically effective amount of ramipril is administered to a patient in multiple daily doses such that the administration of multiple daily dosages of ramipril is more effective than a single daily dose containing an equivalent amount of ramipril.
  • Ramipril can be administered a twice a day, or more than twice a day in any of the dosage forms discussed above.
  • a dosage form with 10 mg of ramipril can be administered to an individual twice daily for a total daily dose of 20 mg of ramipril.
  • a dosage form with 5 mg of ramipril can be administered to an individual four times a day for a total daily dose of 20 mg of ramipril, or a dosage form with 2.5 mg of ramipril can be administered to an individual eight times a for a total daily dose of 20 mg of ramipril.
  • the total daily dose of ramipril can be higher or lower than 20 mg and the multiple daily doses of ramipril can be administered to accommodate the desired total daily dose of ramipril.
  • the dosage of active ingredient, such as ramipril or ramipril in combination with another active agent, in the compositions of the invention may be varied; however, it is necessary that the amount of the active ingredient be such that a suitable dosage form is obtained.
  • the active ingredient may be administered to patients (animals and human) in need of such treatment in dosages that will provide optimal pharmaceutical efficacy.
  • the selected dosage depends upon the desired therapeutic effect, on the route of administration, and on the duration of the treatment.
  • the dose will vary from patient to patient depending upon the nature and severity of disease, the patient's weight, special diets being followed by a patient, concurrent medication, and other factors, recognized by those skilled in the art.
  • ramipril daily dosage levels of between about 0.010 to about 1.5 mg/kg or 0.010 to 1.5 mg/kg of body weight are administered daily to mammalian patients, e.g., humans having a body weight of about 70 kg.
  • the ramipril dosage range will generally be about 1.25 mg to 50 mg or 1.25 mg to 50 mg per patient per day, administered in single or multiple doses.
  • ramipril and the other active agents utilized in accordance with the present invention will vary with the particular cardiovascular disorder, conditions and/or symptoms being treated, the age, weight and physical conditions of the subjects being treated, the severity of the cardiovascular disorder, conditions and/or symptoms, the duration of treatments, the nature of concurrent therapies, the specific dosage form employed, the particular pharmaceutically acceptable carriers utilized, and like factors within the knowledge and expertise of the attending physicians.
  • exemplary safe and effective amounts of ramipril include those amounts mentioned herein, administered one or more times per day, as will be more fully describe herein below.
  • the present invention is also generally directed towards methods of making pharmaceutical compositions with improved stability, bioavailability and shelf-life.
  • the following methods of making pharmaceutical compositions in accordance with the present can be used with any drug.
  • the methods of the present invention are directed to making pharmaceutical compositions comprising any drug that is susceptible to degradation when exposed to the environment or exposed to physical stresses during the manufacturing process.
  • compositions of the present invention can be made by first combining a drug with a blending agent so that the drug is coated with a blending agent before being processed into tablets.
  • Combining the drug with the blending agent can be accomplished by blending, mixing, milling or co-milling, compressing, granulating, suspending, dissolving or precipitating the drug and the blending agent together.
  • the combined drug and blending agent is suitable for use in preparing dosage forms by processes including, but not limited to, dry blend, direct compression formulations and hot melt extrusion processes.
  • the methods of the present invention comprise an ACE inhibitor and more preferably, ramipril.
  • Methods of the present invention comprise combining ramipril with a blending agent. Such methods can also further comprise adding an additive such as, but not limited to, a polymer, diluent, disintegrant or a combination thereof, before or after the ramipril is combined with the blending agent.
  • Combining ramipril with the blending agent can be accomplished by blending, mixing, milling or co-milling, compressing, granulating, suspending, dissolving or precipitating the drug and the blending agent together.
  • the invention contemplates methods comprising combining a blending agent and ramipril before the ramipril is further processed with at least one other active agent and other excipients into a dosage form.
  • the blending agent and ramipril are pre-blended or co-milled before the ramipril is further processed into the formulations of the instant invention.
  • the invention also contemplates methods that further comprise adding additives including, but not limited to, diluents, binders, vehicles, carriers, excipients, binders, disintegrating agents, lubricants, swelling agents, solubilizing agents, wicking agents, cooling agents, preservatives, stabilizers, sweeteners, flavors, polymers, to the pre-blended or co-milled ramipril and blending agent.
  • additives including, but not limited to, diluents, binders, vehicles, carriers, excipients, binders, disintegrating agents, lubricants, swelling agents, solubilizing agents, wicking agents, cooling agents, preservatives, stabilizers, sweeteners, flavors, polymers.
  • additives including, but not limited to, diluents, binders, vehicles, carriers, excipients, binders, disintegrating agents, lubricants, swelling agents, solubilizing agents, wicking agents, cooling agents, preservative
  • Such methods can also further include additional steps comprising combining the pre-blended ramipril and blending agent along with a polymer, diluent, disintegrant or a combination thereof. Further, the methods will comprise the additional step of adding at least one other active agent to the co-milled or pre-blended ramipril. In alternate embodiments, the methods comprise co-milling and/or pre- blending ramipril and at least one other active agent with the blending agent prior to further formulation of ramipril and the other active agent into a dosage form.
  • the methods of the present invention comprise pre-blending ramipril with a blending agent and then co-milling the ramipril and the blending agent. Such methods can also further include additional steps comprising combining the co- milled ramipril and blending agent along with a polymer, diluent, disintegrant or a combination thereof. Further, the methods will comprise the additional step of adding at least one other active agent to the co-milled or pre-blended ramipril. In alternate embodiments, the methods comprise co-milling or pre-blending ramipril and at least one other active agent with the blending agent prior to further formulation of ramipril and the other active agent into a dosage form.
  • the methods of the present invention comprises blending ramipril with a blending agent; co-milling the ramipril and the blending agent and then re-blending the ramipril with the blending agent.
  • Such methods can also further include additional steps comprising combining the ramipril and blending agent along with a polymer, diluent, disintegrant or a combination thereof. Further, the methods will comprise the additional step of adding at least one other active agent to the co-milled or pre-blended ramipril.
  • the methods comprise co-milling or pre-blending ramipril and at least one other active agent with the blending agent prior to further formulation of ramipril and the other active agent into a dosage form.
  • the method of the present invention comprises blending ramipril with a polymer and co-milling the ramipril and polymer with a blending agent. Such methods can also further include additional steps comprising combining the ramipril with a second polymer, diluent, disintegrant or a combination thereof, before or after being co-milled with the blending agent.
  • the methods will comprise the additional step of adding at least one other active agent to the co-milled or pre-blended ramipril.
  • the methods comprise co-milling or pre-blending ramipril and at least one other active agent with the blending agent prior to further formulation of ramipril and the other active agent into a dosage form.
  • the method of making solid oral ramipril pharmaceutical compositions comprises blending coated ramipril with a blending agent; co-milling the coated ramipril and the blending agent; and re-blending the coated ramipril with a blending agent.
  • a polymer, a diluent, a lubricant or a disintegrant can be combined with the ramipril before or after being milled.
  • the methods will comprise the additional step of adding at least one other active agent to the co-milled or pre-blended ramipril.
  • the methods comprise co-milling or pre-blending ramipril and at least one other active agent with the blending agent prior to further formulation of ramipril and the other active agent into a dosage form.
  • one purpose of the pre-blending and co-milling the blending agent and ramipril before the ramipril is further processed into tablets is to facilitate coating the ramipril with the blending agent.
  • the blending agent coats the ramipril.
  • the blending agent coats between about 50% to 100% of the ramipril, or between about 75% to 100% or 50% to 100% of the ramipril, or between about 85% to about 100% or 85% to 100% and most preferably between about 95% to 100% or 95% to 100% .
  • the preferred blending agent is glyceryl behenate
  • ramipril and glyceryl behenate are first co-milled, then followed by additional steps wherein, sodium stearyl fumarate and croscarmellose sodium are added to the ramipril and glyceryl behenate blend.
  • the methods will comprise the additional step of adding at least one other active agent to the co- milled or pre-blended ramipril.
  • the methods comprise co-milling or pre-blending ramipril and at least one other active agent with the blending agent prior to further formulation of ramipril and the other active agent into a dosage form.
  • Figure 1 shows one method of making pharmaceuticals of the present invention comprising GECoated ramipril.
  • GEcoated ramipril is pre-milled though a 60-mesh screen.
  • the milled ramipril is then pre-blended with glyceryl behenate for 15 minutes in a blender that has been grounded to reduce electrostatic charges.
  • Croscarmellose sodium, sodium stearyl fumerate and silicified microcrystalline cellulose are added to the mixture and mixed for another 20 minutes.
  • the co-milled mixture is then passed through a 20-mesh sieve.
  • the sieved mixture is then placed into blender and mixed for an additional 8 minutes.
  • the mixture is then compressed with a tablet press.
  • the tablets finished tablets then can be packaged.
  • This process can be scaled, for example, to about 6 kg, in a 16-quart V-shell
  • Tablets can be produced with a Fette P 1200 24-station press, or similar equipment.
  • compositions made by the above process can be formulated with uncoated ramipril as well.
  • microcrystalline cellulose can be replaced with diluents and fillers including but not limited to Ceolus®, lactose, anhydrous lactose, lactose monohydrate, starch, spray-dried mannitol (Pearlitol 200 SD), Prosolv®
  • SMCC 90 or a combination thereof.
  • glyceryl behenate can be replaced with magnesium stearate.
  • the mixing times and other parameters of the process can be varied to achieve the pharmaceutical compositions of the present invention comprising ramipril, wherein the ramipril has a low rate of degradation compared to current formulations.
  • An article of manufacture as contemplated by the present invention, comprises a container holding a pharmaceutical composition suitable for oral administration of stabilized ramipril in combination with at least one other active agent along with printed labeling instructions providing a discussion of when a particular dosage form should be administered.
  • composition will be contained in any suitable container capable of holding and dispensing the dosage form and which will not significantly interact with the composition and will further be in physical relation with the appropriate labeling advising that a dosage form is more stable and/or bioavailable with extended shelf life.
  • the labeling instructions will be consistent with the methods of treatment as described hereinbefore.
  • the labeling may be associated with the container by any means that maintain a physical proximity of the two, by way of non-limiting example, they may both be contained in a packaging material such as a box or plastic shrink wrap or may be associated with the instructions being bonded to the container such as with glue that does not obscure the labeling instructions or other bonding or holding means.
  • compositions, of the present invention comprising ramipril in combination with at least one other active agent, can be administered to a subject for the treatment of cardiovascular disorders.
  • Cardiovascular disorders include but are not limited to, hypertension, heart failure, congestive heart failure, myocardial infarction, atherosclerotic cardiovascular disease, asymptomatic left ventricular dysfunction, chronic renal insufficiency, and diabetic or hypertensive nephropathy.
  • An embodiment of the subject invention is a pharmaceutical composition
  • a pharmaceutical composition comprising ramipril, another active agent, and a blending agent, wherein the ramipril is coated by the blending agent, and wherein the blending agent is selected from glyceryl behenate, glyceryl stearate, stearyl alcohol, macrogol stearate ether, palmitostearate, ethylene glycol, polyethylene glycol, stearic acid, cetyl alcohol, lauryl alcohol, amylopectin, poloxymer or combinations thereof.
  • the rate of decomposition of the ramipril to ramipril-diketopiperazine is less than about 0.4% by weight during about the first three months.
  • the rate of decomposition of the ramipril to ramipril-diketopiperazine is less than about 3.0% by weight during about the first thirty-six months.
  • the rate of decomposition of the ramipril to ramipril-diketopiperazine is less than about 0.12% by weight, on average, per month.
  • Another embodiment of the subject invention is a pharmaceutical composition
  • a pharmaceutical composition comprising ramipril, another active agent, and a blending agent, wherein the ramipril is coated by a blending agent and wherein the rate of decomposition of the ramipril to ramipril- diketopiperazine is less than about 0.4% of the total weight of ramipril during the first 3 months when the pharmaceutical composition is at room temperature.
  • the rate of decomposition is about 0.4%.
  • Another embodiment of the subject invention is a pharmaceutical composition
  • a pharmaceutical composition comprising ramipril, another active agent, and a blending agent, wherein the ramipril is coated by a blending agent and wherein the rate of decomposition of the ramipril to ramipril- diketopiperazine is less than about 1.0 % of the total weight of ramipril during the first 6 months when the pharmaceutical composition is at room temperature and 60% relative humidity.
  • the rate of decomposition is about 0.75%.
  • Another embodiment of the subject invention is a pharmaceutical composition
  • a pharmaceutical composition comprising ramipril, another active agent, and a blending agent, wherein the ramipril is coated by a blending agent and wherein the rate of decomposition of the ramipril to ramipril- diketopiperazine is less than about 3.0% of the total weight of ramipril during the first 36 months when the pharmaceutical composition is at room temperature.
  • the rate of decomposition is about 2.0%.
  • the rate of decomposition is about 1.5%.
  • Another embodiment of the subject invention is a pharmaceutical composition
  • a pharmaceutical composition comprising ramipril, another active agent, and a blending agent, wherein the ramipril is coated by a blending agent and wherein the rate of decomposition of the ramipril to ramipril- diketopiperazine is less than about 0.15%, on average, of the total weight of ramipril per month when the pharmaceutical compositions are at room temperature.
  • the rate of decomposition is about 0.09% or less.
  • the blending agent is glyceryl behenate.
  • the blending agent is at least
  • the blending agent is at least 1
  • the blending agent is at least 4
  • the ramipril is substantially stable against decomposition into a degradant product.
  • the degradant product is ramipril-diacid or ramipril-diketopiperazine.
  • the ramipril is coated ramipril.
  • the composition is a solid dosage form.
  • the composition is an oral dosage form.
  • the composition is a tablet, caplet or capsule.
  • the composition is a tablet.
  • composition further comprises an excipient.
  • the ramipril is in the amount of about 0.1 mg to 50 mg.
  • the ramipril is in the amount of about 1 mg to 30 mg.
  • the ramipril is in the amount of about 2.5 mg.
  • the ramipril is in the amount of about 5 mg.
  • the ramipril is in the amount of about 10 mg.
  • the ramipril is in the amount of about 15 mg.
  • the ramipril is in the amount of about 20 mg.
  • the active agent is a diuretic, an angiotensin receptor blocker, an ACE inhibitor, a cholesterol lowering drug, a calcium channel blocker, a beta blocker, a glucose lowering agent, or oral hypoglycemics.
  • the active agent is a diuretic.
  • the diuretic is chlorthalidone.
  • the chlorthalidone is in the amount of about 0.1 mg to 50 mg.
  • the chlorthalidone is in the amount of about 1 mg to 30 mg.
  • the chlorthalidone is in the amount of about 6.5 mg.
  • the chlorthalidone is in the amount of about 12.5 mg.
  • the chlorthalidone is in the amount of about 25 mg.
  • the diuretic is hydrochlorothiazide .
  • the hydrochlorothiazide is in the amount of about 0.1 mg to 50 mg.
  • the hydrochlorothiazide is in the amount of about 1 mg to 30 mg.
  • the hydrochlorothiazide is in the amount of about 6.5 mg.
  • the hydrochlorothiazide is in the amount of about 12.5 mg.
  • the hydrochlorothiazide is in the amount of about 25 mg.
  • Another embodiment of the subject invention is a method of making a pharmaceutical composition comprising coating ramipril with a blending agent, wherein the pharmaceutical composition further comprises another active agent.
  • Another embodiment of the subject invention is a method of making a pharmaceutical composition
  • a method of making a pharmaceutical composition comprising: a) pre-blending milled ramipril with a blending agent; and b) combining the product of step a) with another active agent, wherein the blending agent is glyceryl behenate, glyceryl stearate, stearyl alcohol, macrogol stearate ether, palmitostearate, ethylene glycol, polyethylene glycol, stearic acid, cetyl alcohol, lauryl alcohol, amylopectin, poloxymer or combinations thereof.
  • the blending agent is glyceryl behenate, glyceryl stearate, stearyl alcohol, macrogol stearate ether, palmitostearate, ethylene glycol, polyethylene glycol, stearic acid, cetyl alcohol, lauryl alcohol, amylopectin, poloxymer or combinations thereof.
  • Another embodiment of the subject invention is a method of making a pharmaceutical composition
  • a method of making a pharmaceutical composition comprising: a) pre-blending and co-milling ramipril with a blending agent; and b) combining the product of step a) with another active agent, wherein the blending agent is glyceryl behenate, glyceryl stearate, stearyl alcohol, macrogol stearate ether, palmitostearate, ethylene glycol, polyethylene glycol, stearic acid, cetyl alcohol, lauryl alcohol, amylopectin, poloxymer or combinations thereof.
  • the blending agent is glyceryl behenate, glyceryl stearate, stearyl alcohol, macrogol stearate ether, palmitostearate, ethylene glycol, polyethylene glycol, stearic acid, cetyl alcohol, lauryl alcohol, amylopectin, poloxymer or combinations thereof.
  • the method of making a pharmaceutical composition further comprising blending the ramipril with the blending agent before the ramipril and blending agent are co-milled.
  • the method of making a pharmaceutical composition further comprising blending the ramipril with the blending agent after the ramipril and blending agent are co-milled.
  • the method of making a pharmaceutical composition further comprising adding a diluent, lubricant, disintegrant or a combination thereof.
  • the method of making a pharmaceutical composition further comprising compressing the product of step b) into tablets.
  • the blending agent is glyceryl behenate.
  • the blending agent is at least
  • the blending agent is at least 1
  • the blending agent is at least 4
  • the ramipril is coated ramipril.
  • the composition is a solid dosage form.
  • the composition is an oral dosage form.
  • the composition is a tablet, caplet or capsule.
  • the composition is a tablet.
  • the ramipril is in the amount of about 0. 1 mg to 50 mg.
  • the ramipril is in the amount of about 1 mg to 30 mg.
  • the ramipril is in the amount of about 2.5 mg.
  • the ramipril is in the amount of about 5 mg.
  • the ramipril is in the amount of about 10 mg.
  • the ramipril is in the amount of about 15 mg. [0261] In another embodiment of the subject invention, the ramipril is in the amount of about 20 mg.
  • the active agent is a diuretic, an angiotensin receptor blocker, an ACE inhibitor, a cholesterol lowering drug, a calcium channel blocker, a beta blocker, a glucose lowering agent, or oral hypoglycemics.
  • the active agent is a diuretic.
  • the diuretic is chlorthalidone.
  • the chlorthalidone is in the amount of about 0.1 mg to 50 mg.
  • the chlorthalidone is in the amount of about 1 mg to 30 mg.
  • the chlorthalidone is in the amount of about 6.25 mg.
  • the chlorthalidone is in the amount of about 12.5 mg.
  • the chlorthalidone is in the amount of about 25 mg.
  • the diuretic is hydrochlorothiazide.
  • the hydrochlorothiazide is in the amount of about 0.1 mg to 50 mg.
  • the hydrochlorothiazide is in the amount of about 1 mg to 30 mg.
  • the hydrochlorothiazide is in the amount of about 6.5 mg.
  • the hydrochlorothiazide is in the amount of about 12.5 mg.
  • the hydrochlorothiazide is in the amount of about 25 mg.
  • the method of making a pharmaceutical composition further comprising combining the produce of step b) with microcrystalline cellulose and croscarmellose sodium.
  • the present invention includes methods of making a pharmaceutical dosage form such as a tablet that includes ramipril and hydrochlorothiazide, wherein glycerol behenate is used not as a blending agent to coat and stabilize ramipril but as a lubricating agent.
  • glycerol behenate being used as a lubricating agent, other exicipients such as those discussed above can be used in the tablet.
  • Such tablets can contain 2.5 mg of ramipril and 12.5 mg of hydrochlorothiazide, 5 mg of ramipril and 12.5 mg of hydrochlorothiazide, 5 mg of ramipril and 25 mg of hydrochlorothiazide, 10 mg of ramipril and 25 mg of hydrochlorothiazide or 20 mg of ramipril and 25 mg of hydrochlorothiazide.
  • Another embodiment of the subject invention is a product made by the above methods.
  • Another embodiment of the subject invention is a method of treating cardiovascular disorders in a human comprising administering to the human an effective amount of any of the above compositions.
  • the cardiovascular disorder is hypertension, heart failure, congestive heart failure, myocardial infarction, atherosclerotic cardiovascular disease, asymptomatic left ventricular dysfunction, chronic renal insufficiency, and diabetic or hypertensive nephropathy.
  • the ramipril/chlorthalidone combination tablets were made by pre-blending the coated ramipril with glyceryl behenate, sodium stearyl fumarate and croscarmellose sodium in a 16-quart V-shell blender and blending for a suitable mount of time, then mill- blending the mixture through a Quadro Co-mil.
  • Chlorthalidone was then added to the mixture with microcrystalline cellulose, sodium stearyl fumarate and croscarmellose sodium in a 16-quart container and mixed, then compressed on a Stokes B2 tablet press, tooled with 16 stations with 1 A" standard concave (about 100 mg tablet weight) or 5/16" standard concave (about 200 mg tablet weight) double-sided debossed tooling at about 48 rpm.
  • Ramipril/hydrochlorthiazide combination tablets were made by pre-milling coated ramipril (ramipril coated with hydroxypropyl methylcellulose) through a 40 or 60 mesh screens and then pre-blended with a blending agent such as, glyceryl behenate. Hydrochlorthiazide, silicified microcrystalline cellulose and croscarmellose sodium were added and mixed for an additional period of time. The mixture was co-milled through a 20 mesh screen and blended. The mixture was compressed into tablets.
  • This study was conducted as a single-dose, randomized, open-label, three-way crossover design in healthy male and female volunteers. Forty-five subjects (40% - 60% female) were enrolled in the study. Following a 14-day screening period, subjects underwent a two-stage randomization process for treatment group and sequence. Table 1 shows the treatments that were utilized.
  • Serum chemistry blood urea nitrogen (BUN), creatinine, total bilirubin, albumin, alkaline phosphatase, alanine aminotransferase (ALT), aspartate aminotransferase (AST), total protein, potassium, sodium, calcium, chloride, carbon dioxide, gamma glutamyl transferase, triglycerides, total cholesterol, and glucose.
  • BUN blood urea nitrogen
  • ALT alanine aminotransferase
  • AST aspartate aminotransferase
  • total protein potassium, sodium, calcium, chloride, carbon dioxide, gamma glutamyl transferase, triglycerides, total cholesterol, and glucose.
  • WBC white blood cell
  • RBC red blood cell
  • Urinalysis dipstick for protein, glucose, ketones, bilirubin, and blood; if urine was positive for blood then a microscopic examination was performed.
  • test products were administered as a single oral dose taken with 240 mL water.
  • test products There were 3 kinds of test products used in this study:
  • Ramipril/chlorthalidone combination tablets manufactured by King Pharmaceuticals, Inc. 2.5 mg/6.25 mg, 10 mg/12.5 mg, and 20 mg/25 mg.
  • Chlorthalidone commercial 25 mg tablets (chlorthalidone, USP,) manufactured by Mylan Pharmaceuticals, Inc.
  • Chlorthalidone tablets manufactured by King Pharmaceuticals, Inc. 6.25 mg, 12.5 mg, and 25 mg.
  • AUCo. t The area under the whole blood concentration versus time curve, from time 0 to time t, where C t is the last quantifiable concentration, as calculated by the linear trapezoidal method.
  • AUCo.j nf The area under the whole blood concentration versus time curve, from time 0 to infinity, calculated as AUCo- t + Q/K e i, where K e ⁇ is the terminal elimination rate constant.
  • K e i Apparent terminal elimination rate constant, calculated from the linear regression of the terminal linear portion of the ln(concentration) versus time curve, where K is the absolute value of the slope.
  • Venous blood samples (5 mL) for the Pharmacokinetic studies were obtained from an indwelling catheter (heparin flush as needed) or by direct venipuncture. Blood samples were collected at predose (time 0) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36,
  • the assay was validated with respect to accuracy, precision, linearity, sensitivity, and specificity.
  • race 37 subjects were Caucasian, 4 subjects were Hispanic, and 1 subject each was Asian, Black, European/Middle Eastern, and of "other" race.
  • the mean age for all subjects was 25.8 years (range 19 - 48 years), the mean weight was 71.4 kilograms (range 55.8 - 94.3 kilograms), and the mean height was 174.3 centimeters (range 160.0 - 193.0 centimeters).
  • body frame size 5 subjects had a small frame, 33 subjects had a medium frame, and 7 subjects had a large frame.
  • Descriptive statistics including arithmetic mean, standard deviation (SD), coefficient of variation (C V%), standard error of the mean (SEM), number (N), minimum, maximum, and median were presented for whole blood chlorthalidone concentrations at each time point, and for all PK parameters by treatment. Additionally, geometric mean was presented for C max , AUCo-t, and AUC 0- j n f; and harmonic mean was presented for Ti/ 2 . [0299] To evaluate the chlorthalidone bioavailability, analyses of variance (ANOVA) were performed on the In-transformed C max , AUCo-t, and AUCo-inf- The ANOVA model included terms for treatment, period, sequence, and subject within sequence.
  • Example 2 are presented in Figures 2-4.
  • Subjects were enrolled in Treatment Group I, II, III, or IV and received a total of 3 treatments (ramipril-chlorthalidone tablet, ramipril commercial capsule, and ramipril tablet), which were randomized with respect to sequence. All study drugs were administered as a single dose with 240 mL (8 fluid ounces) of water following an overnight fast. Each treatment was separated by a 3 -week washout period.
  • a single dose of these study drugs was administered with 240 mL of water following an overnight fast.
  • the duration of the treatment was nine (9) weeks including screening.
  • Pharmacokinetic analyses were performed using plasma concentrations of ramipril and ramiprilat.
  • the ramipril maximum peak concentrations (C max ) for both the ramipril-chlorthalidone tablets and ramipril tablets tended to be higher than the ramipril commercial capsules following the low dose levels (2.5 mg and 5 mg), but lower following the highest dose level (20 mg).
  • Ramiprilat C max following ramipril-chlorthalidone tablets and ramipril tablets compared to the ramipril commercial capsules was comparable at the lower dose levels (2.5 mg and 5 mg, and 10 mg), but lower following the high dose level (20 mg).
  • the ramipril tablets were dose proportional with respect to ramipril AUCo- I2 and AUCo- 2 4.
  • Example 3 are presented in Figures 5-9.
  • Exemplary tablets of ramipril/hydrochlorthiazide combination tablets were made and evaluated for their stability.
  • Batch A was 2.5 mg of GECoated ramipril (ramipril coated with hydroxypropyl methylcellulose) combined with 6.25 mg of hydrochlorothiazde (HCTZ).
  • Batch B was 5 mg of GECoated ramipril (ramipril coated with hydroxypropyl methylcellulose) combined with 25 mg of hydrochlorothiazde.
  • Results of the statistical analyses for the ramipril assay for exemplary ramipril/HCTZ combination tablets are provided in Table 23.
  • the y-intercept represents the starting assay value of ramipril, while the slope reflects the rate of change in this assay value per month.
  • Results of the statistical analyses for the hydrochlorothiazide assay for exemplary ramipril/hydrochlorothiazide combination tablets are provided in Table 24.
  • the y- intercept represents the starting assay value of hydrochlorothiazide, while the slope reflects the rate of change in this assay value per month.
  • Results of the statistical analyses for the sum of ramipril degradation products for exemplary ramipril/hydrochlorothiazide combination tablets are provided in Table 25.
  • the y-intercept represents the starting assay value of the combined ramipril degradation products, while the slope reflects the rate of change in this assay value per month.
  • Results of the statistical analyses for the ramipril-diketopiperazine content in ramipril/hydrochlorothiazide combination tablets are provided in Table 26.
  • the y-intercept represents the starting assay value of ramipril-diketopiperazine, while the slope reflects the rate of change in this assay value per month.
  • Dissolution analyses were also conducted for ramipril/HCTZ combination tablets.
  • ramipril dissolution statistical analyses were conducted for both the mean dissolution result and the minimum dissolution result observed at each stability time-point. The two analyses were conducted to evaluate the ability of the product to meet the USP staged acceptance criteria. For the statistical analyses, both the mean and minimum dissolution results are compared to the USP Stage 1 acceptance criteria (Q + 5%).
  • Results of the statistical analyses for the ramipril mean dissolution for ramipril/HCTZ combination tablets are provided in Table 27. The rate of change in the results (slope) was not consistently increasing or decreasing, and, in all cases, the absolute value of the change was less than 0.2% per month.
  • Results of the statistical analyses for the ramipril minimum dissolution for ramipril/HCTZ combination tablets are provided in Table 28.
  • the rate of change in the results (slope) was not consistently increasing or decreasing, and, in all cases, the absolute value of the change was less than 0.4% per month.
  • the predicted linear regression line is significantly above the proposed specification limit at the 24 month time-point. Therefore, it is expected that results will ultimately support a 24 month expiration date for this product.
  • This study determined the relative bioavailability, and therefore the bioequivalence, of ramipril-HCTZ 10/25 mg tablets compared with ramipril 10 mg capsules (Altace ® ) and HCTZ 25 mg tablets, administered concomitantly under fasted conditions, in healthy volunteers.
  • the study followed a randomized, open-label, single-dose, 3-way crossover design. Forty-eight (48) healthy adult volunteers (40% - 60% female) were enrolled and randomly assigned to 1 of 6 treatment sequences. Subjects completed a Screening Phase, a Treatment Phase consisting of 3 dosing periods, and an End-of-Study Phase. Each treatment was separated by a 21 -day washout period. Subjects entered the Treatment Phase of the study on Day 1 and received one of the following treatments following an overnight fast:
  • Treatment A 1 x 10 mg/25 mg ramipril-HCTZ tablet with 240 mL of water under fasted conditions.
  • Treatment B 1 * 10 mg ramipril capsule (Altace ® ) plus 1 * 25 mg HCTZ tablet taken concomitantly with 240 mL of water under fasted conditions.
  • Treatment A 2 * 10 mg/12.5 mg ramipril-HCTZ tablets with 240 mL of water.
  • Treatment B 2 x 10 mg ramipril capsules (Altace ® ) plus 1 x 25 mg HCTZ tablet administered concomitantly with 240 mL of water.
  • Treatment C 2 x 10 mg ramipril capsules (Altace ® ) with 240 mL of water.
  • Treatment D 1 x 25 mg HCTZ tablet with 240 mL of water.
  • Pharmacokinetic analyses were performed using plasma concentrations of ramipril, ramiprilat, and HCTZ.
  • Pharmacokinetic parameters included the maximum observed concentration (C max ), time-to-maximum observed concentration (T ma ⁇ ), and area under the plasma concentration-time curve over various time points (AUC 0-t for all compounds, AUCo -I2 for ramipril, AUC 0-24 for ramiprilat and HCTZ, and AUC O-48 for ramiprilat).
  • Ramipril-HCTZ Tablets (Treatment A) Compared to 2 x 10 mg Ramipril Capsules (Altace ® ) (Treatment C) and Compared to 1 x 25 mg HCTZ Tablet (Treatment D)
  • Subjects completed a Screening Phase, a Treatment Phase consisting of 2 dosing periods, and an End-of-Study Phase. The 2 treatments were separated by a 21 -day washout period. Subjects entered the Treatment Phase of the study on Day 1 and received one of the following treatments following an overnight fast:
  • Treatment A 1 x 2.5 mg/12.5 mg ramipril-HCTZ tablet with 240 mL of water.
  • Treatment B 1 x 2.5 mg ramipril capsule (Altace ® ) plus 1 x 12.5 mg HCTZ capsule (Microzide ® ), administered concomitantly with 240 mL of water.
  • Pharmacokinetic analyses were performed using plasma concentrations of ramipril, ramiprilat, and HCTZ.
  • Pharmacokinetic parameters included the maximum observed concentration (C max ), time-to-maximum observed concentration (T max ), and area under the plasma concentration-time curve over various time points (AUC 0-t for all compounds, AUC 0 - I2 for ramipril, AUC 0-24 for ramiprilat and HCTZ, and AUC 0-48 for ramiprilat).
  • Study 4 Relative Bioavailability Results Following 10 mg/25 mg Ramipril-HCTZ Tablet Compared to HCTZ 25 mg Capsule [0373]
  • the purpose of study 4 was to determine the relative bioavailability, and therefore the bioequivalence, of ramipril-HCTZ (10 mg/25 mg) tablets compared with HCTZ 25 mg capsules in healthy volunteers. This was a randomized, open-label, single-dose, 2-way crossover study in healthy young (age 19 - 45 years) adult male and female volunteers. Thirty (30) subjects (50% female) were enrolled and randomly assigned to 1 of 2 treatment sequences; a minimum of 24 subjects was to complete the study.
  • Subjects completed a Screening Phase, a Treatment Phase consisting of 2 dosing periods, and an End-of-Study Phase. The 2 treatments were separated by a 21 -day washout period. Subjects entered the Treatment Phase of the study on Day 1 and received one of the following treatments following an overnight fast: Treatment A: 1 * 10 mg/25 mg ramipril-HCTZ tablet with 240 mL of water.
  • Treatment B 1 x 25 mg HCTZ capsule with 240 mL of water.
  • HCTZ HCTZ.
  • Pharmacokinetic parameters included the maximum observed concentration (C ma ⁇ ), time-to-maximum observed concentration (T max ), apparent terminal elimination rate constant (K c i), terminal elimination half-life (t/,), and area under the plasma concentration-time curve over various time points (AUC 0 . t , AUC 0 - 2 4, and AUC 0- i n f).
  • the objects of the study were to compare the effect (change from baseline) on the diastolic blood pressure of the combination of ramipril and HCTZ after 8 weeks of treatment in patients with Stage 2 essential hypertension and to compare the change from baseline of the systolic blood pressure of the combination of ramipril with HCTZ dosed once daily to ramipril and HCTZ dosed once daily. Further objectives were to compare clinical blood pressure among different patient groups, compare changes from baseline in ambulatory blood pressure in different patient groups and assess safety and tolerance of ramipril plus HCTZ compared to the three monotherapy treatments.
  • the 2- to 4-week Screening/Washout/Placebo-Lead-In Period allowed for up to a cumulative 4-week washout period for subjects on medications with long elimination half-lives, or who had extenuating clinical issues in the judgment of the Investigator. At the end of this period, all subjects were required to meet the following criteria prior to entry into the Treatment Period: • a mean clinic sitting systolic blood pressure between 140 and 180 mm Hg (inclusive) at each of Visits 2 and 3,
  • the mean clinic sitting systolic blood pressure from each of Visit 2 and Visit 3 must be between 140 and 180 mm Hg (inclusive); and the mean clinic SiDBP must be between 100 and 1 15 mm Hg (inclusive) from each of Visit 2 and Visit 3.
  • the difference in clinic SiDBP between Visit 2 and Visit 3 must be ⁇ 10 mm Hg.
  • Subjects who require a longer washout period may be required depending on the antihypertensive therapy of the subject prior to the study, or for other clinical reasons) may continue the placebo lead-in for 2 additional weeks prior to randomization (Visits 2a and 2b).
  • One week will separate Visit 2 from Visit 2a, and one week will separate Visit 2a from Visit 2b. Blood pressure criteria must be met as noted above for Visit 2 (or 2a or 2b, as applicable) and
  • Visit 3a blood pressure values indicate that the Visit 2 (or 2a or 2b, as applicable) and Visit 3 blood pressure criterion will not be met, the subject should be considered a screen failure, and the ABPM session should not be initiated.
  • Additional ECG monitoring may be done if clinically indicated, at the discretion of the
  • the mean clinic sitting systolic blood pressure from each of Visit 2 and Visit 3 must be between 140 and 180 mm Hg (inclusive); and the mean clinic SiDBP must be between 100 and 115 mm Hg (inclusive) from each of Visit 2 and Visit 3.
  • the difference in clinic SiDBP between Visit 2 and Visit 3 must be ⁇ 10 mm Hg.
  • Subjects who require a longer washout period may be required depending on the antihypertensive therapy of the subject prior to the study, or for other clinical reasons) may continue the placebo lead-in for 2 additional weeks prior to randomization (Visits 2a and 2b).
  • One week will separate Visit 2 from Visit 2a, and one week will separate Visit 2a from Visit 2b. Blood pressure criteria must be met as noted above for Visit 2 (or 2a or 2b, as applicable) and Visit 3.
  • Visit 3a blood pressure values indicate that the Visit 2 (or 2a or 2b, as applicable) and Visit 3 blood pressure criterion will not be met, the subject should be considered a screen failure, and the ABPM session should not be initiated.
  • Subjects were titrated to their final dose of study drug over the first 2 weeks of the Treatment Period as noted in Table 39.
  • subjects received ramipril 10 mg with or without HCTZ 12.5 mg, or HCTZ 12.5 mg, according to the randomization schedule.
  • subjects had their dose increased to ramipril 20 mg (administered once daily, or in equally divided doses twice daily), with or without HCTZ 25 mg (administered once daily), or HCTZ 25 mg as noted in Table 39.
  • the subject remained on this dose for the duration of the Treatment Period.
  • 24-hour ambulatory blood pressure monitoring period began one day prior to Visit 7 (i.e., Visit 7a), and concluded the morning of Visit 7.
  • a subject was eligible for enrollment if all of the following criteria apply:
  • ICF informed consent form
  • Subject has either a previous diagnosis of essential hypertension, or has newly diagnosed hypertension according to the JNC 7 guidelines. To qualify for study entry, the subject must have a mean clinic sitting systolic blood pressure between 140 and 180 mm Hg (inclusive) at each of Visits 2 and 3, and a mean clinic SiDBP between 100 and 115 mm Hg (inclusive) at each of Visit 2 (or 2a or 2b, as applicable) and Visit 3.
  • Subject can be safely withdrawn from antihypertensive medications during the Screening/Washout/Placebo Lead-in Period.
  • Subject is male or female between 18 and 80 years of age (inclusive).
  • contraception defined as systemic hormonal contraception (oral, implant, injection, patch, ring), diaphragm with intravaginal spermicide, cervical cap with spermicide, intrauterine device, or condom with spermicide.
  • systemic hormonal contraception oral, implant, injection, patch, ring
  • diaphragm with intravaginal spermicide cervical cap with spermicide
  • intrauterine device intrauterine device
  • condom with spermicide the subject must have used the chosen method of birth control for at least one month/cycle prior to enrollment into the study
  • Subject has a >10 mm Hg difference between the mean SiDBP at Visit 2 (or 2a/2b, as applicable), and the mean SiDBP at Visit 3.
  • Secondary causes of hypertension such as pheochromocytoma, primary aldosteronism, chronic kidney disease, renal artery stenosis, or obstructive sleep apnea (according to the Investigator's judgment).
  • Clinically significant renal disease e.g., serum creatinine >2.5 mg/dL, and/or calculated glomerular filtration rate [GFR] ⁇ 40 mL/minute, based on body surface area, and calculated by the Cockcroft-Gault method.
  • GFR glomerular filtration rate
  • Clinically significant hepatic disease e.g., 2 times the upper limit of normal for alanine aminotransferase [ALT] or aspartate aminotransferase [AST]).
  • alpha-adrenergic blockers e.g., tamsulosin
  • Subject has a history of chronic alcohol consumption and/or drug addiction within the past 2 years (DSM-IV TR).
  • Ramipril-HCTZ induced greater reductions in both clinic and ambulatory BP than HCTZ alone and ramipril 20 mg once-a-day.
  • the following data also shows that clinically meaningful blood pressure reduction can be achieved by administering to patients 20 mg of ramipril alone, either as a once-a-day dose of 20 mg of ramipril or, alternatively, a twice-a-day dose of 10 mg of ramipril.
  • Reductions from baseline were typically greater for the clinic BP derived from device measurements compared to daytime BPs derived from ambulatory BP measurements.
  • Figures 10.1 - 10.2 show a boxplot of change from baseline to end of treatment (Visit 7) in mean sitting diastolic and systolic blood pressure mm Hg) of 341 subjects.
  • the box plot shows the smallest observed change in blood pressure, the upper quartile, the median, the lower quartile and the largest observed change in blood pressure.
  • the once daily combination treatment of 20 mg of ramipril and 25 mg of HCTZ was more effective in lowering sitting diastolic and systolic blood pressure than the monotherapies of 20 mg once daily treatment of ramipril (R-20 mg QD), 25 mg once daily treatment of HCTZ (HCTZ - 25 mg QD) and 10 mg twice daily treatment of ramipril. Additionally, the twice-a-day monotherapy of ramipril was more effective in lowering blood pressure than the once-a-day monotherapy of ramipril.
  • Figures 10.3 - 10.4 show a boxplot of change from baseline to end of treatment (Visit 7) in mean standing diastolic and systolic blood pressure (mm Hg) of 341 subjects.
  • the once daily combination treatment of 20 mg of ramipril and 25 mg of HCTZ was more effective in lowering standing diastolic and systolic blood pressure than the monotherapies of 20 mg once daily treatment of ramipril (R-20 mg QD), 25 mg once daily treatment of HCTZ (HCTZ - 25 mg QD) and 10 mg twice daily treatment of ramipril.
  • the twice-a-day monotherapy of ramipril was more effective in lowering blood pressure than the once-a-day monotherapy of ramipril.
  • Figures 10.5 - 10.6 show a boxplot of change from baseline to the first visit after baseline measurements were taken (Visit 4) in mean sitting diastolic and systolic blood pressure (mm Hg) of 330 subjects.
  • the once daily combination treatment of 20 mg of ramipril and 25 mg of HCTZ was more effective in lowering sitting diastolic and systolic blood pressure than the monotherapies of 20 mg once daily treatment of ramipril (R-20 mg QD), 25 mg once daily treatment of HCTZ (HCTZ - 25 mg QD) and 10 mg twice daily treatment of ramipril.
  • Figures 10.7 - 10.8 show a boxplot of change from baseline to the first visit after baseline measurements were taken (Visit 4) in mean standing diastolic and systolic blood pressure (mm Hg) of 330 subjects.
  • the once daily combination treatment of 20 mg of ramipril and 25 mg of HCTZ was more effective in lowering standing diastolic and systolic blood pressure than the monotherapies of 20 mg once daily treatment of ramipril (R-20 mg QD), 25 mg once daily treatment of HCTZ (HCTZ - 25 mg QD) and 10 mg twice daily treatment of ramipril.
  • Figures 10.9 - 10.10 show a boxplot of change from baseline to end of treatment (Visit 7) in mean 24-hour ambulatory diastolic and systolic blood pressure (mm Hg) of 232 subjects. Changes from baseline in the clinic sitting systolic and diastolic blood pressure were confirmed by the 24 hour ambulatory measurements.
  • the once daily combination treatment of 20 mg of ramipril and 25 mg of HCTZ was more effective in lowering 24-hour ambulatory diastolic and systolic blood pressure than the monotherapies of 20 mg once daily treatment of ramipril (R-20 mg QD), 25 mg once daily treatment of HCTZ (HCTZ - 25 mg QD) and 10 mg twice daily treatment of ramipril. Additionally, the twice-a-day monotherapy of ramipril was more effective in lowering blood pressure than the once-a-day monotherapy of ramipril.
  • Figure 10.1 1.1 shows a plot of mean sitting diastolic blood pressure over time by treatment group.
  • the once daily combination treatment of 20 mg of ramipril and 25 mg of HCTZ was more effective in lowering the mean sitting diastolic blood pressure than the monotherapies of 20 mg once daily treatment of ramipril (R-20 mg QD), 25 mg once daily treatment of HCTZ (HCTZ - 25 mg QD) and 10 mg twice daily treatment of ramipril.
  • Figure 10.1 1.2 shows a plot of change from baseline (Visit 3) in mean sitting diastolic blood pressure over time by treatment group.
  • Figure 10.12.1 shows a plot of mean sitting systolic blood pressure over time by treatment group.
  • the once daily combination treatment of 20 mg of ramipril and 25 mg of HCTZ was more effective in lowering the mean sitting systolic blood pressure than the monotherapies of 20 mg once daily treatment of ramipril (R-20 mg QD), 25 mg once daily treatment of HCTZ (HCTZ - 25 mg QD) and 10 mg twice daily treatment of ramipril.
  • Figure 10.12.1 shows a plot of change from baseline (Visit 3) in mean sitting systolic blood pressure over time by treatment group.
  • the once daily combination treatment of 20 mg of ramipril and 25 mg of HCTZ was more effective in lowering the mean sitting systolic blood pressure than the monotherapies of 20 mg once daily treatment of ramipril (R-20 mg QD), 25 mg once daily treatment of HCTZ (HCTZ - 25 mg QD) and 10 mg twice daily treatment of ramipril.
  • the twice daily monotherapy of ramipril was more effective in lowering the mean sitting systolic blood pressure than the once daily monotherapy of ramipril.
  • Figures 10.13 and 10.14 show plots of the mean ambulatory diastolic and systolic blood pressure (mm Hg) at baseline (Visit 3) by hour and treatment group.
  • Figures 10.15 and 10.16 show plots of the mean ambulatory diastolic and systolic blood pressure (mm Hg) at the end of treatment (Visit 7) by hour and treatment group.
  • Figures 10.17 - 10.18 show plots of change from baseline (Visit 3) to the end of treatment (Visit 7) in mean ambulatory diastolic and systolic blood pressure (mm Hg) by hour and treatment group.
  • Tables 40 and 41 show that the combination therapy of ramipril and HCTZ was more effective in lowering the ambulatory SBP and DBP at hours 22, 23, and 24 than ramipril and HCTZ monotherapies. Additionally, as shown in Tables 40 and 41 the combination therapy of ramipril and HCTZ showed a reduction in the increase in ambulatory trough blood pressure. Trough blood pressure is defined as blood pressure at 22-24 hours following the morning dose of the study drug, and 10-12 hours following the evening dose of the study drug.
  • the ABPM start time at Visit 7 will define Hour 0 for hourly calculations at both Visits : 3 and 7.
  • i n number of subjects with data for the specified hour at Visit 3 and 1 Visit 7, .
  • SD standard deviation.
  • the ABPM start time at Visit 7 will define Hour 0 for hourly calculations at both Visits 3 and 7.
  • n number of subjects with data for the specified hour at Visit 3 and visit 7.
  • SD standard deviation.
  • Table 42 shows the average baseline sitting systolic (SiSBP) and sitting diastolic blood pressure (SiSBP) and the average baseline awake ambulatory blood pressure of the treatment group.
  • Table 42 also shows the mean reduction in sitting systolic and diastolic blood pressure and ambulatory blood pressure from baseline at the end of treatment of the combination therapy group administered ramipril and HCTZ versus the monotherapy groups.
  • Table 42 also shows the change in sitting systolic and diastolic blood pressure and ambulatory blood pressure at the end of treatment between the combination therapy group and the three monotherapy groups.
  • Table 42 shows that the combination therapy of ramipril and HCTZ was more effective in reducing sitting systolic blood pressure and the sitting diastolic blood pressure than the ramipril or HCTZ monotherapies. Also, as shown in Table 42, the combination therapy of ramipril and HCTZ was more effective in reducing mean 24-hour systolic blood pressure and the mean 24-hour diastolic blood pressure, measured as the awake ambulatory blood pressure, than the ramipril or HCTZ monotherapies. Achieving better 24-hour hypertension control with a once daily fixed dose of this combination will help reduce the risks associated with the increase in blood pressure that sometimes occurs at the end of dosing interval with monotherapy treatment.
  • Tables 43-46 show the reduction from baseline at the end of treatment in mean sitting systolic blood pressure and the sitting diastolic blood pressure by subgroup.
  • Table 43 shows the reduction from baseline at the end of treatment in mean sitting systolic blood pressure and the sitting diastolic blood pressure in individuals of African descent and individuals of non- African descent.
  • Table 43 shows that the combination therapy of ramipril and HCTZ was more effective than the other monotherapies in lowering the blood pressure of individuals of African and non-African descent. Additionally, Table 43 shows that the combination therapy of ramipril and HCTZ was as effective in individuals of African descent as individuals of non African descent. This, however, was not the case for the HCTZ and ramipril monotherapies.
  • the once daily and twice daily monotherapies of ramipril was shown to be more effective in individuals of non- African descent than individuals of African descent.
  • the HCTZ monotherapy was shown to be more effective in individuals of African descent than individuals of non African descent.
  • the twice-a-day monotherapy of ramipril was more effective in lowering the blood pressure in individuals of non- African descent than the once- a-day monotherapy of ramipril.
  • Table 44 shows the reduction from baseline at the end of treatment in mean systolic blood pressure and diastolic blood pressure in males and females.
  • Table 44 shows that the combination therapy of ramipril and HCTZ was more effective than the other monotherapies in lowering the blood pressure in males and females. Table 44 also shows that the combination therapy of ramipril and HCTZ was more effective in females than in males.
  • the once daily monotherapy of ramipril was shown to be more effective in males than females.
  • the once daily HCTZ monotherapy was shown to be more effective in females than males.
  • the twice daily administration of ramipril monotherapy was more effective in reducing the systolic blood pressure and diastolic blood pressure in females and the systolic blood pressure in males than the once daily monotherapy administration of ramipril.
  • Table 45 shows the reduction from baseline to the end of treatment in mean systolic blood pressure and diastolic blood pressure in individuals younger than 65 years old and individuals 65 years and older.
  • Table 45 shows that the combination therapy of ramipril and HCTZ was more effective in reducing the systolic blood pressure and diastolic blood pressure than ramipril or HCTZ monotherapies in individuals less than 65 years old and more effective in reducing the diastolic blood pressure in individuals 65 years of age or more. Additionally, the once daily and twice daily ramipril monotherapies were shown to be more effective in individuals 65 years of age or older than individuals less than 65 years of age. Also, the twice daily ramipril therapy was more effective in lowering the systolic blood pressure in individuals 65 years or older than the single daily dose of ramipril.
  • Table 45 shows the reduction from baseline at the end of treatment in mean sitting systolic blood pressure and the sitting diastolic blood pressure in naive individuals and individuals who were not naive.
  • Na ⁇ ve individuals are individuals who had not previously received any medication for the treatment of hypertension until they were enrolled in the study.
  • Non-na ⁇ ve individuals are individuals who have previously received medication for the treatment of hypertension before being enrolled in the study.
  • Table 46 shows that the combination therapy of ramipril and HCTZ was more effective in reducing the systolic blood pressure and the diastolic blood pressure than ramipril or HCTZ monotherapies in both naive and non-na ⁇ ve individuals. Table 46 also shows that the combination therapy of ramipril and HCTZ was more effective in na ⁇ ve individuals than non-na ⁇ ve individuals. This, however, was not the case for the HCTZ and the ramipril once daily monotherapies.
  • the once daily and twice daily monotherapies of ramipril was shown to be more effective in lowering the diastolic blood pressure in na ⁇ ve individuals than non-na ⁇ ve individuals but more effective in lowering the systolic blood pressure in non-na ⁇ ve individuals than na ⁇ ve individuals.
  • the HCTZ monotherapy was shown to be more effective in non-na ⁇ ve individuals than na ⁇ ve individuals.
  • Table 47 shows the adverse events according to the various treatment groups.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des compositions pharmaceutiques et des procédés de traitement de troubles cardiovasculaires en administrant des compositions pharmaceutiques comprenant du ramipril en combinaison à d'autres agents actifs, tels qu'un comprimé contenant du ramipril et de l'hydrochlorothiazide. Les compositions de la présente invention ont une stabilité améliorée du ramipril qui est moins susceptible à la dégradation par rapport à d'autres compositions comprenant du ramipril seul ou en combinaison à un autre agent actif.
PCT/US2008/005451 2007-04-27 2008-04-28 Procédés de traitement de l'hypertension WO2008134047A1 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US92679607P 2007-04-27 2007-04-27
US60/926,796 2007-04-27
US93078307P 2007-05-17 2007-05-17
US60/930,783 2007-05-17
US93099207P 2007-05-18 2007-05-18
US60/930,992 2007-05-18

Publications (1)

Publication Number Publication Date
WO2008134047A1 true WO2008134047A1 (fr) 2008-11-06

Family

ID=39926005

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/005451 WO2008134047A1 (fr) 2007-04-27 2008-04-28 Procédés de traitement de l'hypertension

Country Status (1)

Country Link
WO (1) WO2008134047A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111220730A (zh) * 2020-01-19 2020-06-02 合肥科颖医药科技有限公司 一种厄贝沙坦氢氯噻嗪复方制剂中有关物质的分析方法
CN115068434A (zh) * 2022-08-03 2022-09-20 昆山龙灯瑞迪制药有限公司 一种雷米普利片的制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060159742A1 (en) * 2004-11-05 2006-07-20 King Pharmaceutical Research & Development, Inc. Stabilized individually coated ramipril particles, compositions and methods

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060159742A1 (en) * 2004-11-05 2006-07-20 King Pharmaceutical Research & Development, Inc. Stabilized individually coated ramipril particles, compositions and methods

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GOYAL ET AL.: "Assessment of single versus twice daily dosing of ramipril by ambulatory blood pressure monitoring in patients similar to those included in the HOPE study", JOURNAL OF HUMAN HYPERTENSION, vol. 21, pages 525 - 530 *
MEISEL ET AL.: "Clinical pharmacokinetics of ramipril", CLINICAL PHARMACOKINETICS, vol. 26, no. 1, 1994, pages 7 - 15, XP009085688 *
SPIEKER ET AL.: "Efficacy and Safety of Ramipril Therapy in Hypertension after Renal Transplantation", INTERNATIONAL JOURNAL OF ANGIOLOGY, vol. 4, 1995, pages 41 - 43 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111220730A (zh) * 2020-01-19 2020-06-02 合肥科颖医药科技有限公司 一种厄贝沙坦氢氯噻嗪复方制剂中有关物质的分析方法
CN115068434A (zh) * 2022-08-03 2022-09-20 昆山龙灯瑞迪制药有限公司 一种雷米普利片的制备方法
CN115068434B (zh) * 2022-08-03 2023-05-09 昆山龙灯瑞迪制药有限公司 一种雷米普利片的制备方法

Similar Documents

Publication Publication Date Title
US20060134213A1 (en) Stabilized ramipril compositions and methods of making
RU2464014C2 (ru) Комбинированный препарат для лечения сердечно-сосудистых заболеваний на основе теории хронотерапии
RU2616516C2 (ru) Фармацевтическая композиция, содержащая олмесартана медоксомил и розувастатин или его соль
EP2273985B1 (fr) Capsule pour la prévention des maladies cardiovasculaires
WO2006063737A1 (fr) Therapie combinatoire impliquant le telmisartan et l'hydrochlorothiazide
US20060159747A1 (en) Telmisartan and hydrochlorothiazide combination therapy
CA2715350C (fr) Composition pharmaceutique solide incluant un antagoniste non peptidique du recepteur de l'angiotensine ii et un diuretique
BRPI0716302A2 (pt) composiÇço farmacÊutica oral de liberaÇço atrasda por tempo de intervalo e mÉtodo para preparar um composiÇço farmacÊutica oral de liberaÇço atrasada por tempo de intervalo
US20120045505A1 (en) Fixed dose drug combination formulations
CA2801020A1 (fr) Preparation pharmaceutique stable contenant du telmisartan et de l'hydrochlorothiazide
US20070116762A1 (en) Compositions of stabilized ramipril in combination with another active agent
WO2013100630A1 (fr) Formulation de combinaison de doses fixes comprenant du losartan, de l'amlodipine et de l'hydrochlorothiazide
WO2008134047A1 (fr) Procédés de traitement de l'hypertension
US20160045497A1 (en) Complex preparation including valsartan and rosuvastatin calcium and manufacturing method therefor
WO2008025450A1 (fr) procédés de diminution des taux de glucose
MX2007007046A (en) Combination therapy comprising telmisartan and hydrochlorothiazide

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08754131

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08754131

Country of ref document: EP

Kind code of ref document: A1